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ABSTRACT
Human Immunodeficiency Virus (HIV) is the cause of Acquired Immune Deficiency Syndrome
(AIDS) and has killed over 25 million people since the disease was first recognized in 1981. As of
2007, 33 million people globally are infected with HIV and this number is growing.1 HIV infects and
depletes CD4+ helper T cells, affecting the ability of the immune system to defend the host against
common infections. While anti-retroviral therapy has decreased morbidity and mortality, these drugs
are not curative. In addition, they are beyond the financial reach of many HIV infected patients. Thus,
the development of strategies to control HIV spread is a high priority. The most relevant animal
model for studying HIV is the Simian Immunodeficiency Virus (SIV) - infected rhesus monkey.
While HIV research has focused on studying peripheral blood specimens, mucosal sites have recently
been identified as a focal point for HIV replication and tissue destruction. They are usually the sites
of primary infection in the setting of sexual transmission and they are also important sites of immune
depletion. If methods for controlling the replication of the virus early after infection in mucosal sites
are available, it may be possible to eliminate the virus prior to systemic spread.
While strategies for generating strong neutralizing antibody responses have not yet been developed,
emerging data suggest that CD8+ cytotoxic T cells can contribute substantially to early virus control.
It is important to study CD8+ T cells in the setting of SIV infection in rhesus monkeys, particularly
in mucosal sites, using functional as well as transcriptional assays. One of the challenges in studying
mucosal cellular immunity is the limited number of cells available in biopsies, making traditional
assay systems such as flow cytometry very difficult to employ. Here, technologies for isolating rare
cell populations and extracting RNA from these cells for gene expression analysis were developed.
These technologies were then applied to peripheral blood specimens, looking at gene expression
differences between virus-specific CD8+ T cells in Mamu-A*01+ and Mamu-A*02+ monkeys. The
ultimate goal of these studies is to gain a better understanding of SIV immunopathogenesis (as a
model for HIV immunopathogenesis) and to find a way to control or eliminate the virus.
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CHAPTER 1: Introduction
Human Immunodeficiency Virus (HIV) is the cause of Acquired Immune Deficiency Syndrome
(AIDS) and has killed over 25 million people since the disease was first recognized in 1981. As
of 2007, 33 million people globally are infected with HIV and this number is growing.' HIV
infects and depletes CD4+ helper T cells, affecting the ability of the immune system to defend
the host against common infections. While anti-retroviral therapy has decreased morbidity and
mortality, these drugs are not curative. In addition, they are beyond the financial reach of many
HIV patients. Thus, the development of strategies to control HIV spread is a high priority.
Understanding of the biology underlying HIV disease progression is essential for developing
effective therapies and an effective vaccine. Part of the challenge in clarifying AIDS
pathogenesis lies in the lack of adequate assay systems to probe the questions we need to answer.
In the space of cellular immunity, one of the challenges lies in the limited amount of information
that can be obtained by traditional assays such as ELISPOT and intracellular cytokine staining
(ICS). In addition, cell number limitations in particular anatomical compartments such as mucosa,
make it very difficult to employ traditional assay systems, which typically require millions of
cells. Development of novel technologies for studying cellular immunity in limited numbers of
cells in the setting of SIV infection can help us gain a better understanding of SIV
immunopathogenesis (as a model for HIV immunopathogenesis) and to find a way to control or
eliminate it.
HIV Background
HIV is a retrovirus and is a member of the lentivirus family. Due to its low-fidelity replication,
viral mutants are rapidly created, causing a viral swarm or quasi-species inside the host.2-4 This
ability to mutate allows HIV to adapt to and evade host immune responses and also makes it
extremely difficult to contain.5 ,6
Structure
HIV has two copies of single-stranded RNA, enclosed by a conical shell composed of the viral
capsid protein. Each strand of RNA is tightly encapsulated by nucleocapsid proteins that protect
the RNA from nucleases. 7' 8 Reverse transcriptase and integrase are encoded by the RNA and are
integral for development and replication of the virion. 9 Matrix proteins surround the viral capsid,
ensuring the integrity of the virion. Virions are formed when capsid buds off from the host cells,
taking along some of the membrane containing the viral envelope glycoproteins gp120 and gp41.
Genome
HIV contains major genes that are common to all retroviruses: gag, env, and pol. Gag is a
structural gene that encodes for a number of proteins that are necessary for the infrastructure of
the virus. Env encodes for the glycoproteins gpl20 and gp41 which are embedded in viral
envelope and are required for viral entry into host cells. Pol encodes for viral enzymes needed
for replication, including reverse transcriptase, integrase, and protease. Other accessory genes
such as tat, vpr, rev, nef vif and vpu enhance HIV replication and likely contribute to viral
pathogenicity.
Primate SIV model
Simian Immunodeficiency Virus (SIV) has become the model of choice for studying the
pathogenesis and transmission of HIV because the SIV infection of rhesus monkeys (Macaca
Mulatta) shares many of the same pathogenic features of HIV-1 infection in humans." The
primate SIV model has enabled researchers to prospectively design vaccine and challenge
experiments, something that is impossible in humans.
Immune responses to HIV
Both the innate and the adaptive immune responses will likely be important in the control of HIV
replication and pathogenesis. The innate immune response is the earliest response and can kill
infected cells through cytolytic mechanisms or can amplify the immune response through
cytokines and chemokines. The adaptive immune response consists of the humoral arm and the
cellular arm. The humoral immune response works by directing antibodies against viral Env to
potentially inactivate or clear the virus. The cellular immune response targets HIV indirectly by
killing cells that harbor the virus.
Innate immune response
The innate immune response can act rapidly because it uses extant cells and mediators." Natural
killer cells (NK), granulocytes, and possibly y6-T cells provide the initial line of defense upon
stimulation by chemical signals at the site of infection. 12-15 NK cells and y6-T cells can kill
infected cells through cytolytic mechanisms while neutrophils release antimicrobial defensins.12
15 Host macrophages and dendritic cells also play a large role at an early stage after infection by
presenting viral antigens and by secreting cytokines and chemokines to amplify the immune
response. There is still much that is not known about the power of the innate immune system to
control HIV. However, with time, the innate immune response gives way to the adaptive immune
response, which requires presentation of viral antigens on cell surface MHC molecules.
Humoral immune response
While many viruses are controlled by host antibodies, the natural antibody response to HIV is
too late, too weak, and not protective. The humoral immune response takes several weeks after
infection to develop, which is much too late to be effective in controlling HIV spread." The
importance of the humoral response, however, is evident in the number of ways HIV has evolved
to evade host antibodies. 16 For example, the Env proteins gpl20 and gp41, which are most
accessible to antibody binding, are heavily glycosylated and can form trimeric complexes that
prevent antibody access to vulnerable domains of the envelope.16-18 The more vulnerable variable
loops of gpl20 should be prime targets for neutralizing antibodies but, unfortunately, the loops
are too variable to be recognized by the highly focused neutralizing antibodies that develop
following infection. Increasing the effectiveness of the humoral response to HIV will require
tremendous innovation in immunogen design, a clear and logical method for evaluating
immunogens, and thorough structural and molecular analyses of current neutralizing antibodies
and Env proteins. 16' 19 The current inability of the humoral immune response to neutralize HIV
suggests that the burden of HIV control lies with the cellular arm of the immune system and that
for a vaccine to be successful, a focus on improving the cellular immune response may be
necessary.
Cellular immune response
The cellular arm of the immune system is active at an early stage (approximately one week post-
infection) and plays a major role in fighting many viral infections. In HIV, studies have shown
that CD8+ cytotoxic T lymphocytes (CTLs) play a large role in the control of HIV replication
and spread. 20 Soon after the discovery of HIV, CD8+ T cells were found to inhibit viral
replication in autologous CD4+ T lymphocytes. 21 CTL effector molecules include perforin,
granzyme and Fas, as well as soluble factors such as beta-chemokines (RANTES, MIP-la and
MIP-10) and other poorly defined factors. 11,22 The emergence of virus-specific CTL response
correlates temporally with a decrease in viral loads and poor CTL response is associated with
poor viral control.23,24 Depletion of CD8+ lymphocytes in an SIV primate model results in high
viral loads and development of lethal SIV infection. 25-27 However, clearance of HIV is always
incomplete, even in the presence of a robust CD8+ T cell response. Some have attributed the
failure for viral control to the ineffective response of virus-specific CD4+ T cells. 28,29 Others
have suggested that the continuous state of immune activation fuels viral persistence, leading to
CTL dysfunction or exhaustion.30-32 New findings also suggest that viral escape, MHC
polymorphisms, and the kinetics of cell killing are other factors contributing to failure in
controlling HIV replication and pathogenesis. 33 While the cellular immune response to HIV is
the most intensely studied part of the immune response to HIV, there is still much we do not
understand about why the CTL response is not sufficient to control HIV replication. With the
development of new technologies, such as gene expression profiling and bioinformatics, we have
a chance to probe more intensely the underlying host-virus biology with the hope of finding
ways to augment the cellular immune response. However, while the cellular immune response
thus far provides the best control of HIV, CD8+ T cells probably do not account for all HIV
containment. 34 There may therefore be other mechanisms contributing to virus control. A vaccine
that engages all aspects of the immune system will likely provide the best protection against HIV.
HIV as a mucosal pathogen
While most HIV researchers have focused on studying peripheral blood specimens, mucosal sites
have recently been identified as focal points for HIV replication and tissue destruction. They are
usually the sites of primary infection in the setting of sexual transmission and they are also sites
of immune depletion.35 In nonhuman primates, simian immunodeficiency virus (SIV) can be
transmitted without epithelial damage. This may also be true of HIV in humans. There is a need
to study HIV at the mucosal level because it is the site of first infection and also the site of most
significant CD4+ T cell depletion. 36 For a vaccine to be effective, it may need to act at the
mucosal level.37 -40 Antigen-specific CD8+ T lymphocytes are the predominant cellular defense
against viral infections including HIV and SIV.24'41 From these observations, it is evident that a
study of antigen-specific CD8+ T lymphocytes in mucosal compartments in the setting of SIV
infection will be essential for understanding the underlying biology of HIV infection. If methods
for controlling the replication of the virus early after infection in mucosal sites are available, it
may be possible to eliminate the virus prior to systemic spread.
Technologies used to study cellular immune responses
Standard methods for studying cellular immune responses include enzyme-linked
immunosorbent spot (ELISPOT) and intracellular cytokine staining (ICS).
The ELISPOT assay is based on the ELISA immunoassay and can be used to identify and
enumerate cytokine-producing cells. In HIV-infected individuals, the IFN-gamma ELISPOT
assay has been used to identify HIV-specific CD8+ T cells. ELISPOT is attractive as an assay
because it is rapid, inexpensive, easy to use, and sensitive. However, there are several limitations,
including a need for large cell numbers for each evaluated sample and the uncertainty of whether
all HIV-specific CD8+ T cells can be identified based on their IFN-gamma production following
peptide stimulation.42
ICS is an assay that can detect single cell expression of cytokines following stimulation with
specific antigens.43 ICS allows for simultaneous detection, quantification, and phenotypic
characterization of each cell.43 Cells are first permeabilized and then stained with cytokine
antibodies. Flow cytometric analysis is used to determine the amount of cytokine produced or
accumulated. The major advantage of ICS over the ELISPOT assay is the ability to measure
multiple parameters in the same cell. However, there are limitations in this assay technology,
including a need for large cell numbers per sample, and the difficulty in performing ICS on
mucosal samples due to the chronic activation of the cells in these tissues.
Challenges of Studying Mucosal T Cell Immunity
One of the major challenges in the study of mucosal T lymphocyte immunity is the limitation in
the number of antigen-specific T lymphocytes that can be extracted from mucosal biopsies.
Traditional methods of studying lymphocytes, such as ICS and ELISPOT, require large cell
samples (millions of cells), which are impossible to obtain from the small biopsy specimens that
can be sampled from mucosal compartments. In addition, these assay systems only extract
limited information from the cells (ie. presence of cell surface receptors and production of a
handful of cytokines).
Therefore, it is important, both for research purposes and for clinical trial applications, to
develop appropriate assay systems designed for working with small numbers of cells in an easy
and reproducible fashion and that would allow for additional information to be gathered from the
cells, including gene expression data.
Gene Expression profiling as a new tool to study cell biology
The identity and abundance of mRNA species within a cell dictate, to a large extent, the
biological potential of that cell.44 While post-transcriptional mechanisms modify protein
expression in many ways, most cellular changes begin from changes in gene transcription.
Recent advent of microarray technology has made it possible to assess the global mRNA profile
of cells.
The use of miniaturized microarrays for gene expression profiling was first described in 1995 by
Schena et al using a microtiter plate containing 48 cDNA probes.45 Since then, this tool has been
developed extensively and can now probe tens of thousands of genes in parallel and can process
multiple samples at a time on a single chip. Microarrays consist of an arrayed series of
thousands of microscopic spots of DNA oligonucleotides, containing picomoles of a specific
DNA sequence. These oligonucleotides act as probes to hybridize a cDNA or aRNA sample
(target). Probe-target hybridization is then detected and quantified by detection of fluorophore-,
silver-, or chemiluminescence-labeled targets to determine relative abundance of nucleic acid
sequences in the target. In standard microarrays, the probes are attached to a solid surface, which
can be glass or silicon, via a covalent bond. Other microarray platforms (such as Illumina), use
microscopic beads. DNA Microarrays can be used to measure changes in expression levels, to
detect single nucleotide polymorphisms (SNPs), in genotyping or in resequencing mutant
genomes.
Over the past 15 years, microarrays have been used extensively to help scientists take a global
view of biological systems. While unable to assess aspects of cellular regulation, such as
translational control or intracellular compartmentalization, the evaluating of coding mRNA
provides a direct representation of transcriptional and post-transcriptional regulation.46 For
immunologists, this technology has allowed a glimpse into the "immunological genome" defined
as the inventory of genes expressed in different immune system cells and the ways in which
those transcripts are connected in regulatory networks and vary during differentiation and
immune responses. 46 Microarrays have been used to explore perturbations associated with
specific immunological diseases in order to identify key cellular or molecular pathways active in
the setting of those diseases. 47-50 Studies have attempted to identify gene 'signatures' associated
with various hematopoietic cell subpopulations, 5 human leukocytes, 52 and an assortment of
tissues representing the mouse immune system.53 The Novartis Symatlas project analyzed over
60 organs in humans and mice, some of which corresponded to sorted cell populations. 54 The
Genentech IRIS project analyzed the gene profile for a number of immune cell subpopulations
including CD4 T cells, CD8 T cells, NK cells, DCs, and neutrophils.5 5
The first study in HIV using DNA microarrays was done by Geiss et al in 2000 and looked at
host cell gene expression following infection of a CEM cell line with HIV.56 Since then,
microarray studies in human immune cells have helped to reveal novel potential mechanisms of
HIV-mediated pathogenesis. Studies have addressed gene modulation associated with immune
dysregulation, susceptibility to apoptosis, virus replication and viral persistence. 57
Microarray studies on HIV-infected PBMCs in vitro have shown that viral envelope facilitate
virus replication by upregulating proviral cytokines, chemokines, and transcription factors with
long-terminal repeat (LTR) expression. 58' 59 Greater activation of p38 MAPK pathway genes
associated with R5 gpl20 versus X4 gpl20 indicated a potential mechanism for favoring R5
virus replication. 59-6 1 The HIV viral protein R (vpr) has been implicated in down-modulation of
immune-response genes required for accessory cell function and cell cycle genes. 6 2-64 In vivo
PBMC microarray studies have elucidated gene correlates of viremia such as low IL-7 receptor a
expression and high perforin expression in viremic patient PBMCs and not in 12 aviremic,
untreated patients. 65 Genes involved in immature T lymphocyte differentiation, apoptosis, HIV
replication, and homeostasis have been shown in PBMCs to be correlated with clinical status and
disease progression. 66 Microarray studies in CD4+ T cells have confirmed previously suggested
pro-apoptotic mechanisms of CD4+ T-cell induced cell death as well as the role of Nef in
enhancing virus replication in CD4+ T cells through a Nef-mediated cholesterol biosynthesis
pathway.57,67-71 In vivo CD4+ T cells studies have shown up-regulation of genes required for
virus production, assembly, and release, including genes associated with transcriptional
modulation, RNA processing, and protein modification/trafficking. 72
Microarray studies looking at HIV-mediated latency have revealed several candidate
mechanisms contributing to latency in vitro and may possibly act in vivo such as transcriptional
quiescence, up-regulation of transcriptional repressors, inhibition of RNA metabolism and
processing, down-regulation of surface receptors to evade immune recognition, and up-
regulation of virus entry receptors and translation machinery. 56
Microarray studies of HIV infection and replication in macrophages have confirmed the pro-
inflammatory gene commitment thought to enhance virus replication and persistence. HIV-
infected macrophages up-regulate IFN/NF-KB-responsive chemokines and cytokines thought to
enhance virus dissemination by promoting recruitment of CD4+ T cells and other macrophages
to the infection site.58,73 Up-regulation of cytoskeletal reorganization genes has been identified to
enhance virus fusion to host cell membranes.58 Proviral transcription factors are also up-
regulated when macrophages are stimulated with gpl20, indicating a potential for envelope
interactions to mediate activation independent of infection. 74
Microarray studies have also uncovered a gene-to-function relationship between anti-apoptotic
genes and greater cell survival.75 Finally, microarrays have been used to obtain genetic
correlates of immune modulation pre-and post-ART treatment or associated with vaccine trials.
While the use of microarrays in studying HIV infection seems to be ubiquitous, microarray
studies using whole tissues from HIV-infected individuals have been limited.57 Often, mixed
populations of cells have to be assayed from PBMCs and mucosa due to cell number and
technology limitation. Development of tools to allow for microarray studies to be conducted on
small focused subpopulations of cells will be extremely useful.
CHAPTER 2: Cell capture and release of epitope-specific
CD8+ T lymphocytes
Introduction
The study of virus-specific CD8+ T cells in the setting of HIV or SIV infection may potentially
reveal important mechanisms in viral pathogenesis and lead to new strategies for viral
containment. A challenge in studying these small populations of cells lies in the lack of
appropriate assay systems for evaluating small cell numbers. Traditional methods of studying
lymphocytes, such as ELISPOT and intracellular cytokine staining (ICS), require large cell
samples (millions of cells), which are impossible to obtain from the small biopsy specimens that
can be sampled from mucosal compartments. In addition, these assay systems are capable of
extracting only a limited amount of information from the cells, namely a handful of cell surface
receptors and the production of a few cytokines.
Gene expression analysis using microarray technology is a powerful tool for probing host
immune responses and disease pathogenesis in the setting of HIV or SIV infection. With the
development of appropriate assays for working with small cell numbers, virus-specific CD8+ T
cell populations in human or primate models can be probed at the transcriptional level.
With gene expression analysis of virus-specific CD8+ T cells being the final goal, there are two
challenges that must be addressed. The first challenge is to capture the virus-specific CD8+ T
cells and separate them from the total lymphocyte population. The captured population needs to
be >95% pure and the assay system should not result in substantial cell loss. The second
challenge is to extract high quality RNA from the isolated virus-specific CD8+ T cells and
amplify the RNA if necessary. The first challenged will be addressed in this chapter and the
second one will be addressed in the following chapter.
There are three different methods of cell capture that can potentially be used to isolate virus-
specific CD8+ T cells. The first is immuno-magnetic separation using beads. The second is to
develop a microfluidic system that will use an ELISA-like surface chemistry. The last is
fluorescence-activated cell sorting (FACS).
Immuno-magnetic cell separation
Immuno-magnetic separation has been used for isolating cells for a number of biological
applications. 76-80 This method relies on having monoclonal antibodies that can help distinguish
between cell types to be separated. There are two basic methods for performing immuno-
magnetic separation: the tube-based method and the column-based method. The tube-based
method uses micron-sized beads that can be selected using a magnet and the column-based
method uses nano-sized particles that must pass through a ferromagnetic spheres column to
increase cell capture capacity. 80
The two most commonly used magnetic beads systems are the MACS microbeads and the Dynal
dynabeads. MACS microbeads are superparamagnetic particles 50 nm in diameter and
composed of dextran and iron oxide.80  These beads need to pass through a ferromagnetic
spheres column to increase cell capture capacity and various columns are available through
Miltenyi Biotec. In general, two types of Miltenyi columns, 'MS' and 'LS' columns are
optimized for positive selection and two others, 'LD' and 'CS' columns are optimized for
depletion. Dynabeads are polystyrene spherical beads with a core of iron oxide. 8° They are
2.8 um in diameter and usually need to be removed from the cell surface before further analysis
of isolated cell populations.
To isolate virus epitope-specific CD8+ T lymphocytes from a total lymphocyte population, these
cells can be labeled via their T cell receptors with the appropriate MHC class I tetramer
conjugated to phycoerythrin (PE) or other fluorescent dyes. There is a MACS anti-PE bead that
can bind to the PE-labeled tetramer associated with the epitope-specific CD8+ T cells and
facilitate isolation of this rare cell population. There is no anti-PE Dynabead and therefore, a
secondary anti-PE antibody would have to be used in combination with the Dynal mouse IgG
cleavable bead system to do this cell isolation. Both methods have their advantages and
disadvantages. The MACS system has the advantage of using beads that are directly linked to
the PE labeled tetramer positive cells and FACS can be employed on these labeled cells without
need to remove the beads. This system, however, has the disadvantage of using smaller (50 nm)
beads that may not have enough mass to successfully retain cells. In addition, a column
separation can result in heavy cell loss. Dynabeads have the advantage of having a greater
surface area for interacting with cells than the MACS beads and could potentially retain the
bead-cell conjugates better. However, there are several disadvantages to the system. There are
no anti-PE dynabeads and therefore attachment would have to occur through the use of a
secondary antibody. Second, the anti-mouse IgG antibody on the bead can potentially bind to
exposed Fc portions of cell surface receptors of mouse antigen presenting cells. One way to
circumvent this problem is by blocking the beads with mouse anti-FcRY after incubation with
the secondary antibody. Lastly, dynabeads are too large for FACS and need to be removed
before sorting via DNase treatment, adding another level of complexity and contributing to
additional cell loss. It is unclear which system would work better and, therefore, both will be
tried.
Integrated Microfluidic Devices
Because they employ small volumes and are amenable to automation, microfluidic devices
provide a potentially important platform for studying small populations of cells in a high
throughput fashion. Microfluidic devices offer other advantages, including reproducibility of
data because of limited user manipulations, rapid processing time, ease of use, infrequent
contamination, and ability to integrate multiple components. Microfluidic devices have been
developed for a variety of biological applications, including cell capture,81-84 PCR,85-91 chemical
cytometry,92 and microarray analysis. 9 3 -9 5 In addition, significant advances in polymers and
substrates used to create these microfluidic devices have been made. 96-99
However, most of the microfluidic systems developed to date do not meet the requirements of a
device for purifying small numbers of specific cells and carrying out RNA analysis on large
numbers of specimens. They either require complicated accessory equipment,84 allow for
specific cell capture but not release,100-104 allow for cell capture and release but in an equipment
intensive and non-high-throughput manner,' 0 5 or perform cell concentrating but not specific cell
sorting. 82,106 The development of a microfluidic system that is inexpensive, easy to use, and can
both capture specific immune cell populations and release them for subsequent applications such
as RNA analysis is needed to study virus-specific CD8+ T lymphocyte populations.
Poly dimethyl siloxane (PDMS) - based microfluidic systems, pioneered in George Whitesides'
laboratory at Harvard University, can be high throughput, rapid, specific, amenable for use under
sterile conditions and can be associated with less cell loss than traditional FACS because of their
small size.' 07 PDMS has advantages over other substrates such as glass and silicon because of its
low cost and ease of processing. 10 8 Surface chemistry that enables specific binding of PE-labeled
tetramer bound cells can be created. Depending on chamber shape and dimensions, a design that
minimizes cell loss but maximizes sorting efficiency (as measured by sorting time and purity of
sorted population) can be developed. The speed of introducing the cells into the chamber,
washing conditions, collection conditions, tubing preparation, and magnet strength are all critical
parameters to consider. The purity of the collected cells can be analyzed by flow cytometric
analysis or fluorescent microscopy.
Fluorescent-activated cell sorting (FACS)
FACS is a vital tool in biological research and clinical diagnostics, and particularly in stem cell
research.109-115 A heterogeneous population of cells can be purified into fractions containing a
single cell type based on a combination of user-defined parameters. Cells in suspension and
labeled with fluorescent tags are pressurized into a narrow and directed fluid stream. 116 The cells
file in a single line past an analysis point at which one or more laser beams are directed. Any
fluorescent tags on the cells are excited by the laser and this signal is collected by an array of
photo-detectors and optical filters. These signals indicate to the computer how to divert the
droplets of cells that file past the analysis point.
FACS has become a powerful tool in biotechnology, facilitating research and development in
areas such as drug screening, protein engineering, and cell signal profiling." 17 FACS has some
disadvantages. Because particles are analyzed individually, the process of cell sorting is slow.
Top high-speed flow cytometers perform at approximately 1x105 drops per second. 116 In addition,
cell loss is high. However, the factor that is most critical to gene expression analysis is high
purity (>95%) of the assayed cell population and FACS provides this.
Materials and Methods
Mice and immunization
Six- to eight-week-old female BALB/c mice were purchased from Charles River Laboratories
(Wilmington, MA) and maintained under specific-pathogen-free conditions. Research on mice
was approved by the Beth Israel Deaconess Institutional Animal Care and Use Committee.
Groups of mice were immunized either intraperitoneally with rVac-gpl60 (2 x 107 PFU) or
intramuscularly with rAd-gpl40 (2 x 107 particles) or DNA-gpl20 (50 pg of DNA in a 100 tpl
total injection volume; 50 ptl was delivered into each quadriceps muscle). Ten weeks after the
first immunization, mice were boosted with both homologous and heterologous combinations of
immunogens using the previously mentioned vectors via the same route and with the same
quantity as described for the priming immunization." 8
Rhesus monkeys
Three Mamu-A*01+ Indian-origin rhesus monkeys (Macaca mulatta), chronically infected with
SIVmac251, were used for experiments. These animals were maintained in accordance with the
guidelines of the Committee on Animals for the Harvard Medical School and the Guide for the
Careand Use of Laboratory Animals.
Antibodies, tetramers, and peptides
Tetrameric H-2Dd complexes folded with gpl20 p18 epitope peptide (RGPGRAFVTI) were
prepared as previously described,1 19 and conjugated to Streptavidin-PE (DAKO). The antibodies
used in this study were directly coupled phycoerythrin (PE), and allophycocyanin (APC). The
following anti-mouse monoclonal antibodies were used: anti-CD8a (clone 53-6.7; eBiosciences),
and rat anti-mouse Fc Block (clone 2.4G2; BD Pharmingen).
Immunomagnetic Separation
Spleens from BALB/c mice were harvested in RPMI 1640 medium containing 40 U of heparin
per ml. Splenocytes or lymphocytes were isolated from individual mice and peripheral blood
mononuclear cells were isolated using Lympholyte-M (Cedarlane). RBCs were lysed by using
ACK buffer (0.15 M NH4Cl, 1 mM KHOC3, and 0.1 mM disodium EDTA) when indicated by
the experiment. The cells were then washed with PBS/2%FBS and counted.
Dynal CELLection Pan Mouse IgG Kit selection of CD8+ T cells
Cleavable IgG dynabeads (Invitrogen) were added to mouse anti-PE (Biolegend; Clone PE001)
at a concentration of 25 ul of beads to 1 ul of 0.5 mg/ml anti-PE. The beads were incubated with
the anti-PE for 30 min at 4oC, rocking, and then washed twice and resuspended in 25 ul of
PBS/0.5%BSA. Mouse PBMCs were isolated as described above and were blocked with 2 ul rat
anti-mouse Fc Block (clone 2.4G2; BD Pharmingen) for every 106 PBMCs, and incubated for 15
min at 4oC. The cells were then stained with PE-conjugated anti-CD8 (clone 53-6.7;
eBiosciences) and incubated for 15 min at RT and washed twice. The dynabeads coated with
anti-PE were added to the cells at a concentration of 5 ul beads/anti-PE to 107 cells. In addition,
2 ul of rat anti-mouse Fc Block (clone 2.4G2; BD Pharmingen) was added and the mixture was
rocked for 30 min at 40C. The cell and bead mixture was then washed and resuspended in media
according to manufacturer (Invitrogen) specifications. DNase I was added to the samples
according to manufacturer (Invitrogen) instructions, cleaving off the dynabeads, leaving free
CD8+ T cells behind. The beads were separated from the cells using a magnet and the cells
were spun down at 6,700 rpm for 5 min to remove free cleaved antibodies. The collected cell
pellet was fixed with PBS-l% formaldehyde. Samples were collected on an LSR II instrument
(BD Biosciences) and analyzed using the FlowJo software (TreeStar).
Dynal CELLection Pan Mouse IgG Kit selection of epitope-specific CD8+ T cells
Mouse PBMCs were isolated as described above. CD8+ T lymphocytes were purified with
negative selection using the CD8a+ T cell isolation kit for mouse (Miltenyi Biotec). The cells
were stained with PE-conjugated tetramer (H-2Dd/pl8) and anti-PE coated dynabeads (as
described above) were incubated with the cells, along with 2 ul of rat anti-mouse Fc Block (clone
2.4G2; BD Pharmingen). The cells/beads were washed and the dynabeads were cleaved off
according to manufacturer specifications (Invitrogen). The cells were then stained with APC-
conjugated anti-CD8 (clone 53-6.7; eBiosciences) and fixed with PBS-l% formaldehyde.
Samples were collected on an LSR II instrument (BD Biosciences) and analyzed using the
FlowJo software (TreeStar).
Miltenyi immuno-magnetic isolation of epitope-specific CD8+ T cells
Mouse PBMCs were isolated as described above. CD8+ T lymphocytes were purified with
negative selection using the CD8a+ T cell isolation kit for mouse (Miltenyi Biotec) or CD8+ T
cell isolation kit for non-human primates (Miltenyi Biotec). Epitope-specific CD8+ T cells were
then isolated by staining the cells with PE-conjugated tetramer (H-2Dd/pl8 for mice cells or
Gag-pl ic for monkey cells) for 15 min at 40 C, washing with PBS/2%FBS and incubating with
20 ul Anti-PE Microbeads (Miltenyi Biotec) per 107 cells for 15 min at 40C, washing with PBS
pH 7.2, 0.5% BSA and 2 mM EDTA and applying the sample to the Miltenyi manual MS
columns, Automacs, or Multimacs. The collected positive fraction was fixed with PBS-1%
formaldehyde. Samples were collected on an LSR II instrument (BD Biosciences) and analyzed
using the FlowJo software (TreeStar).
Design of microfluidic channels
Microfluidic channels were made by curing a prepolymer of polydimethylsiloxane (PDMS) upon
a master, which was fabricated by standard photolithography. 07 In brief, negative photoresist
was spun upon a silicon wafer to a specified height. A particular pattern of interest was designed
and printed upon a transparency to mask off regions of the photoresist. The photoresist was
exposed to ultraviolet light (UV), which crosslinked regions exposed to UV. Those regions
masked by the patterned transparency remained uncrosslinked. The uncrosslinked photoresist
was removed and the wafer was silanized.
A prepolymer of PDMS (1:10 curing agent : base) was poured upon the silanized wafer and the
masters were baked for at least 4 hours at 70C. To ease in the removal of PDMS, ethanol was
added to the master as the PDMS was peeled away from the master. Holes were punched at the
inlets and outlets of the PDMS mold with a syringe. With a plasma sealer, the glass and PDMS
was exposed to 1 min of plasma and the two surfaces were immediately brought together,
resulting in a permanent seal. The channels were placed upon a 1200 C hotplate for at least 30
min to ensure a seal and sterilize the channels.
Patterning of the microfluidic channel with antibodies using the cross-linker GMBS
The glass was silanized within 15 min after plasma-sealing the PDMS to glass. The channel was
rinsed with ethanol before injecting in 4% (v/v) 3-mercaptopropyltrimethoxysilane (in
ethanol). The channels were incubated with silane for 1 hr at room temperature, then rinsed with
ethanol to remove excess silane. To activate the silane, 0.28% v/v 4-Maleimidobutyric acid
sulfo-N-succinimidyl ester (GMBS; in ethanol) was added for 15 min at room
temperature. Again, the channel was rinsed thoroughly with ethanol to remove excess
reagent. After drying the channels with a stream of nitrogen, phosphate-buffered saline (PBS)
was added.
Functionalization of the surface of the microfluidic channels
Channels consisting of stamps of a clear polymer, polydimethylsiloxane (PDMS), enabled
visualization of the cells within the channel. These stamps of PDMS were sealed to cleaned
glass microscope slides to enable imaging with an inverted microscope. Prior to loading cells
into the microfluidic channel, the surface of the channel was functionalized to bind tetramer-
positive CD8+ T cells. In brief, the surface was coated with 3-mercaptopropyltrimethoxysilane
for 1 h, and activated the silane with 0.28% v/v 4-Maleimidobutyric acid sulfo-N-succinimidyl
ester (GMBS). In the case of direct binding of antibody to GMBS, anti-phycoerythrin (Anti-PE)
antibody (Biolegend) was then added at a concentration of 0.15 mg/ml in PBS and bound to the
GMBS. For the chemisty involving a neutravidin and biotin interaction, after the GMBS
coverage and wash, neutravidin was then injected into the channel at a concentration of
10 ug/ml in PBS and incubated for 2 hours at 40C, followed by a rinse with PBS. Anti-PE
(Biolegend) was biotinylated in-house according to the protocol in the Molecular Probes
Handbook and was added to the channels at a concentration of 10ug/ml and incubated overnight
at 4oC. The channels were then blocked with 1-10% bovine serum albumin (BSA) in phosphate-
buffered saline (PBS) for one hour at room temperature to prevent non-specific binding of
tetramer-negative cells to the functionalized surface of the microfluidic channel. This blocking
was crucial to prevent significant background since the percentage of tetramer-positive T cells is
low (-1%).
Loading of cells into channels
A purified population of CD8+ T cells was obtained using the CD8+ T cell isolation kit (mouse
or monkey) as described above. Prior to loading the CD8+ T cells into the channels, the cells
were stained with PE-conjugated H-2Dd/pl8 tetramer for 15 min at 40 C then washed with
PBS/2%BSA. The cells were then resuspended in PBS at a concentration of 8,300 cells/ul
according to previous titrations. Using a syringe pump to obtain a slow and steady flow in the
channel, a volume of cells equivalent to the volume of the channels was loaded. The cells were
incubated in the channels for 5 min at room temperature to allow the cells to bind to the surface.
The entire device was kept in the dark to prevent photobleaching of the PE-labeled
tetramers. After 5 min, we used a syringe pump to rinse the channels with buffer (PBS/i%BSA)
to remove any non-specific cells from the channel.
Testing antibody coverage of microfluidic channels containing biotin-avidin chemistry
Anti-PE (Biolegend) was biotinylated (Invitrogen) according to the protocol in the Molecular
Probes Handbook. 50 ul of 10 ug/ml biotinylated anti-PE was incubated in the channels coated
with neutravidin (described above) at 4oC for 18 hours. The channels were then washed twice
with filtered and degassed PBS/l%BSA/0.09%Azide (wash buffer) then blocked with 100 ul of
PBS/5% BSA for 2 hours at room temperature. The channels were washed twice with 100 ul of
wash buffer. Free phycoerythrin (PE) at a molar ratio of 2:1 to the biotinylated anti-PE was
added and incubated in the dark for 20 min at room temperature. The channels were then
washed twice with 100 ul of wash buffer and placed in 4oC until imaging.
Counting total cells bound
Microfluidic channels were sealed to the microscopy slides in order to mount the channels upon
a standard-sized, microscope stage. After binding the tetramer-positive cells to the channel and
removing the unbound cells, each region of the channel was imaged and the number of
fluorescent PE-labeled tetramer positive cells was counted. By counting the total number of
fluorescent cells and comparing it to the total number of cells injected into the channel, the
percentage of tetramer positive CD8+ T cells bound was determined.
Results
A number of approaches for isolating epitope-specific CD8+ T lymphocytes were explored,
including immuno-magnetic separation, microfluidic cell sorting, and fluorescence-activated cell
sorting (FACS). Each method was optimized and the methods were compared for their ability to
isolate pure cell populations.
Immuno-magnetic cell separation
Two immuno-magnetic cell separation systems were investigated: Dynal and Miltenyi. In both
systems, experiments showed that a two-round purification procedure was necessary to obtain
the highest purity of epitope-specific CD8+ T cells. A first round was done to select for CD8+ T
cell and a second round of purification was used to select for epitope-specific CD8+ T cells.
Using the Dynal CELLection Pan Mouse IgG Kit with an anti-PE secondary antibody, CD8+ T
cells were isolated with 96.4+0.9% purity (Fig. 2.1). However, the Dynal system was not able
to purify epitope-specific CD8+ T cells, using tetramers, yielding purities of less than 20% (data
not shown) and with substantial cell losses.
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Figure 2.1. Murine CD8+ T cell isolation with Dynabeads. The two plots were generated in
two separate experiments.
The Miltenyi system was explored as another option for a two-round purification of epitope-
specific CD8+ T cells. One can perform a negative selection with the Miltenyi CD8+ T cell
isolation kit followed by positive selection of the epitope-specific CD8+ T cells with Miltenyi
anti-PE microbeads.
Using the Miltenyi CD8+ T cell isolation kit followed by positive selection of epitope-specific
CD8+ T cells with Miltenyi anti-PE microbeads, a 36-fold enrichment of epitope-specific CD8+
T cells (initial 2.7% to final 96.8%) in the murine system (Fig. 2.2) and a 38-fold enrichment
(initial 2.34% to final 89.5%) in the nonhuman primate system was achieved (Fig. 2.3). These
experiments were performed with either the Miltenyi manual MS columns or the Miltenyi
Automacs.
A B
1A X IO 8 . . 2.66 UK
15DK 973
10 1 1 10 x0 0 10K 1K 00K 20K
10 FSC
co
10
Figure 2.2. Positive selection of murine epitope-specific CD8+ T lymphocytes (p18+) with
Miltenyi Microbeads using a two-step purification protocol. (A) Total cell population before
two-step purification. (B) Gating strategy (C) Purified epitope-specific CD8+ T cell population.
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Figure 2.3. Positive selection of rhesus monkey epitope-specific CD8+ T lymphocytes
(pllC+) with Miltenyi Microbeads using a two-step purification protocol. (A) Total cell
population before two-step purification. (B) Gating strategy. (C) Purified epitope-specific CD8+
T cell population.
However, repeated experiments showed that neither the manual columns nor the Automacs
consistently provided epitope-specific CD8+ T cell purities above 80%. For gene expression
analysis, purities should be greater than 95%. The manual columns and Automacs are also not
optimal because they are not high-throughput.
In collaboration with Miltenyi Biotec, we tested a Multi-Macs cell sorter under development in
their R&D laboratories. This cell sorter was similar to the Miltenyi Automacs but could process
24 samples in parallel. Upon testing our application with this sorter, however, we found that cell
purities were inconsistent in repeated experiments, varying between 10% and 80% purity using
similar experimental conditions (Fig. 2.4).
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Figure 2.4. Isolation of epitope-specific CD8+ T lymphocytes using Miltenyi Multimacs
with microbeads. All three samples were processed similarly.
We attempted to optimize the system by varying the amount of antibody-coated microbeads used
and by lysing red blood cells to eliminate them from the final lymphocyte population. While
lysing red blood cells improved CD8+ T cell purity, the final purity of epitope-specific CD8+
lymphocytes did not improve (Fig. 2.5). Decreasing amounts of microbeads that were used also
did not improve the purity of the final cell populations (Fig. 2.6).
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Figure 2.5. Difference in purity of CD8+ T cells and epitope-specific CD8+ T cells with and
without lysis of red blood cells (RBCs).
8390 1 9
92.1% CD8+
75 0.4
., ,j6o.1
60%
pl!C+
0.2
00
10000
1n n
j I
20 ul microbeads
(standard) 10 ul microbeads
0000 10000
00 38.6 44.4 409 47.8
100 100
104. 10
16.8 03 10.7 0.61 1 6' . o 1 1 o 0
1 10 100 1000 10000 1 10 100 1000 10000
O Tetramer+ (Mamu-A*01/ pl 1C)
Figure 2.6. Difference in purity of epitope-specific CD8+ T cells with decreased amounts of
Miltenyi anti-phycoerythrin (anti-PE) microbeads. The standard protocol according to the
manufacturer (Miltenyi Biotec) indicates 20ul microbeads for every 107 cells.
Microfluidic cell sorter
A poly dimethyl siloxane (PDMS)-based microfluidic system for cell sorting was developed as
described in the Materials and Methods section of this chapter. The system was first tested for
isolation of epitope-specific CD8+ T cells using cleavable dynabeads (CELLection Pan Mouse
IgG Kit) combined with an APC conjugated anti-phycoerythrin (PE) antibody adsorbed onto the
PDMS surface. This method yielded very low epitope-specific CD8+ T cell purity (<10%) and
was associated with high cell losses. In this system, the dynabeads had to be cleaved off before
the cells could pass through the flow cytometer for analysis. These results suggested that this
cleavage did not operate efficiently and, as a result, led to high cell losses as well as low cell
purities.
The use of microbeads for this procedure was then explored. Miltenyi anti-PE Microbeads are
small and do not need to be removed prior to flow cytometric analysis. Microfluidic channels
were prepared as described in the Materials and Methods section of this chapter and the channels
were incubated overnight with anti-PE, allowing the antibody to attach to the surface through the
use of a cross-linker (GMBS). A number of different anti-PE antibodies (Biolegend, Sigma, and
Stemsep) were tested. Different BSA concentrations in the blocking buffer were also tested.
Channel design was also varied by adding posts to increase surface area for cell-antibody
interaction (Fig. 2.7). In addition, other variables such as duration of incubation, flow rates and
wash volumes were manipulated to select the optimal conditions for epitope-specific CD8+ T
cell isolation.
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Figure 2.7. Mask and schematic of diamond-shaped microfluidic chamber with poles.
The highest purity of epitope-specific CD8+ T cells obtained was 63% (3632 tetramer-specific
cells/ 5298 total cells in the whole field) (Fig. 2.8). Few T cells were captured in a control non-
coated chamber (0 tetramer binding cells /111-131 total cells). This was achieved using the
coated chamber (0 tetramer binding cells /111-131 total cells). This was achieved using the
Biolegend anti-PE antibody with 10% BSA block, incubation time of 20 min, and 80 ul of wash
buffer at flow rates of 10-20 ul/min.
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Figure 2.8. Capture of epitope-specific CD8+ T lymphocytes using anti-phycoerythrin (PE)
antibodies and PDMS-based microfluidic system. (A) Microfluidic chambers are coated with
anti-PE and total cells stained with PE-tetramer are flowed through the chambers. (B) Tetramer
positive cells are visualized with red fluorescence (indicated by arrow). A purity of 63% was
achieved.
It was not possible to obtain epitope-specific CD8+ cells with greater than 63% purity using this
this particular chemistry. Therefore, other approaches were investigated.
In a different approach, the strong biotin-avidin interaction (Kd=10-13M) was utilized to maintain
the anti-PE antibody on the surface of the chamber. The Biolegend anti-PE was biotinylated as
described in the Materials and Methods section of this chapter and we attached neutravidin to the
silanized glass surface of the chambers by way of a cross-linker (GMBS). The channels were
then incubated with the biotinylated anti-PE. The shape of the channel was also changed to a
rectangular one with rounded edges because diamond-shaped design trapped cells in its corners
(Fig. 2.9).
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Figure 2.9. Rectangular microfluidic cell sorter with biotin-avidin chemistry. (A) Chambers
are rectangular with rounded edges with and without posts. (B) Biotinylated anti-PE is linked to
the surface through a neutravidin-biotin interaction.
Using this new microfluidic design, anti-PE coverage of the surface was evaluated by incubating
the chambers with free phycoerythrin. Coverage was complete and uniform in the channels with
the posts, showing no non-specific binding in the negative control (Fig. 2.10). The areas around
the posts showed the greatest fluorescence because the posts allow for stacking of antibody all
along its length and when visualized from above, exhibits high fluorescence intensity. In
between the posts, the antibody is collected only in one layer and therefore in contrast, looks
dark. The chambers without the post also showed uniform coverage of free phycoerythrin (data
not shown). Since the posts provide greater surface area for cell-antibody interaction, they will
likely be the best for cell sorting.
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Figure 2.10. Biotinylated anti-PE coverage of microfluidic chamber surface. Chambers are
incubated with free PE and visualized with a fluorescent microscope. (A) Bright field view
shows snapshot of chamber with posts. (B) Fluorescent view shows biotin-anti-PE coating
visualized as bright circles around the posts. (C) Negative control chamber
To understand dynamic cell attachment behavior at different shear rates, a Hele-Shaw device can
be used (Fig. 2.11).104 This device can be used to optimize flow rates so that the greatest number
of epitope-specific CD8+ T cell are captured with the lowest amount of non-specific binding.
These experimental results are pending.
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Figure 2.11. Hele-Shaw Device. Shear stress varies along the length of the device and by
observing where antigen-specific CD8+ T cells attach, the optimal flow rate for greatest specific
cell capture and smallest non-specific attachment can be determined.
Fluorescence-Activated Cell Sorting (FACS)
While a microfluidic cell sorter is being developed, a fluorescence-activated cell sorter (FACS)
will be used for isolation of epitope-specific CD8+ T cells. FACS consistently provides greater
than 99% pure populations of epitope-specific CD8+ T cells. While FACS is time-consuming
and is associated with high cell loss (approximately 50%), the purity of the cells that are obtained
is unsurpassed.
Discussion
Dynabeads facilitated the isolation of CD8+ T cells from total PBMCs to a high purity as shown
in Figure 2.1. However, they were not capable of isolating virus epitope-specific CD8+ T
cells. This suggests that these beads are more useful for sorting large populations but not rare
cell populations such as epitope-specific CD8+ T cells, which can comprise only 1-2% of a total
cell population. It is possible that the cleavage process, which involves rigorous pipetting and
shaking, may disturb the tetramer binding to the cells, since this is not nearly as high affinity an
interaction as the one between the CD8 molecule and an anti-CD8 antibody.
Miltenyi beads had an advantage over dynabeads in that they did not need to be removed before
an analysis of the cells isolated using the beads. This quality may have contributed to the
superiority of their capabilities in isolating virus epitope-specific CD8+ T cells. In addition, the
Miltenyi system does not require a secondary antibody and is therefore simpler. Instead, the
anti-PE was linked directly to the microbeads and was added to PE labeled tetramer positive
cells without an intermediate linker. However, results from our studies suggest that even this
system is not able to consistently isolate highly purified populations of virus epitope-specific
CD8+ T cells. Immuno-magnetic separation using the Multimacs, the manual MS columns, or
the Automacs did not yield cells of high enough purity for our needs. Virus epitope-specific
cells can represent a very small percentage of total mononuclear cells, especially in the setting of
chronic infection. While immuno-magnetic separation is practical for isolation of large
subpopulations of cells, it is neither strong enough nor specific enough to isolate subpopulations
that represent only 1-2% of a cell population. A more stringent system is therefore needed to
capture and separate these rare cell populations.
Microfluidic channels represent a potentially useful alternative to immuno-magnetic separation
because it involves limited user manipulations, rapid processing time, ease of use, reduction in
contamination, and can integrate multiple components. However, this technology will take more
time to reach maturity. Upon successful capture and release of virus epitope-specific cells from
a larger total cell population, one can imagine integrating a module for downstream RNA
extraction that can be used for gene expression analysis. A chamber with multiple inlets would
allow the introduction of lysis buffer and other reagents into a compartment with the cells. The
RNA could be collected on silicon coated columns built into the chamber or on beads packed in
the chamber. Initially, the collected RNA could be release through an outlet into an eppendorf
for macroscale RNA processing. Based on work by other laboratories, 120 it is feasible to design
an addition process for cDNA amplification via solid phase reaction on beads or columns. A
heating element would need to be attached to the device as well as inlets for reaction buffers and
dNTPs. For each of the inlets, microvalves and micropumps could be engineered, 120, 12 1 and the
timing could be controlled by a computer-run system. The ultimate result would be an integrated
device capable of sorting virus epitope-specific CD8+ T cells from a total lymphocyte population
and could perform downstream RNA extraction and cDNA amplification for gene expression
analysis.
Since these technologies do not yet exist, fluorescence-activated cell sorter (FACS) is the best
available technology to use to isolate virus epitope-specific CD8+ T cells. FACS provides a very
high purity of isolated cell subpopulations. For gene expression analysis, purity of the cell
population to be studied is of utmost importance so that one can be certain that the expression
levels seen on an array originate from the cells being studied. However, FACS does have
disadvantages, namely high cell loss (30-50%) and long processing time. The processing of
cells from PBMC extraction to cell isolation using FACS may induce changes in the biology of
the cells that are distinct from the changes associated with the biologic events being studied.
However, since cells are processed the same way, comparison of gene expression profiles should
reveal differences associated with biologic events and not sample processing.
CHAPTER 3: Development of techniques for RNA extraction,
amplification, and gene expression analysis using limited
numbers of cells
Introduction
The validity of gene expression data is dependent on using good quality RNA. While adequate
amounts of high integrity RNA can be obtained from millions of cells, it is difficult to obtain
high integrity RNA from limited numbers of cells. However, often, as is in the case of studying
virus epitope-specific CD8+ T cells, the cell population of interest is small. Therefore, the
development of techniques for extraction of high yield and high quality RNA and subsequent
amplification and gene expression analysis is of tremendous importance.
RNA Integrity
RNA can be rapidly digested by nearly ubiquitous RNase enzymes, compromising its analysis.
RNA integrity has been evaluated using agarose gel electrophoresis stained with ethidium
bromide, producing two bands comprising the 28S and 18S ribosomal RNA species.122 RNA is
considered to be of high quality if the ratio of 28S:18S bands is about 2.0 or higher. However,
this method is highly subjective, requiring human interpretation of gel images. A newer and
more automated method for evaluating the quality of extracted RNA uses the concept of the
RNA Integrity Number (RIN) calculated by the Agilent Bioanalyzer using a Bayesian
approach. 122,123 The RIN is calculated using a combination of a number of different features to
allow for robust measurement. These features include the total RNA ratio (fraction of area in
18S and 28S regions compared to total area under the curve), the height of the 28S peak, the fast
area ratio, and the marker height. 12 2 RNA with a RIN of 7 or greater is adequate for downstream
applications such as RT-PCR, amplification, and gene expression analysis.
RNA Isolation
There are two characteristics to consider in RNA isolation: quality and quantity. When working
with limited number of cells, very few RNA isolation methods are capable of yielding
measurable quantities of high integrity RNA. Individual eukaryotic cells contain on the order of
1-10 pg of total RNA, varying based on organism, species, tissue type, and viability of the
cells." 15 While several studies have been published comparing RNA yield and quality from
different extraction methods, varying results are suggested by different scientists and often
results contradict each other.12 4 -12 9 RNA extraction is a very sensitive procedure and can yield
different results in different hands. For example, for one group, the Trizol method provided
poor quality RNA and low yields, 124 while for another group, it proved to be superior to any
other methods. 128 In many instances, the type of tissue or cell in question as well as the nature of
downstream applications is pertinent to the choice of RNA extraction method.
There are three basic types of methods for extraction of RNA: a tube-based phase separation
extraction method (ie. Trizol), 130,131 a silica-gel membrane-based spin-column method (ie.
RNeasy Micro-Kit or Arcturus PicoPure Kit), and a paramagnetic oligo(d)T-bead method (ie.
gMACS). Column methods often have the advantage of very high purity, since the sample is
passed through a mesh filter, but have the disadvantage of high RNA loss. Tube-based phase
separation methods can result in high yields because there is no column, but there is the potential
of contaminants in the final RNA sample.
RNA Amplification
Microarray analysis require a minimum of 25 ng of unamplified aRNA or 1.5 ug of amplified
poly(A)+ RNA for the Illumina platform, and 2-5 ug of unamplified poly(A)+ RNA for the
Affymetrix platform. It is often not possible to obtain this much RNA from sorted cell
populations from mucosal biopsies and peripheral blood. Therefore, amplification techniques
are essential for studies involving microarray analysis of cellular subpopulations. Most
amplification techniques are based on the work of Eberwine, which uses in vitro transcription of
RNA to achieve linear increases of RNA concentration. 132 The first strand cDNA is synthesized
by an RNA-dependent reverse transcriptase, and is primed by a phage promoter (T7, T3, or SP6)
linked oligo-dT primer that binds to the poly(A)+ tail of mRNA. 133 The second strand cDNA is
then synthesized with a DNA polymerase I followed by aRNA synthesis from the cDNA
template using an RNA polymerase corresponding with the promoter sequence (T7, T3, or
SP6)." 5 The second round of amplification is similar to the first except first strand cDNA
synthesis is primed using random primers and a T7, T3, or SP6 promoter-linked oligo-dT primer
is used for second strand synthesis." 5 aRNA products are biased toward the 3' end of the
transcript because of the initial priming at the poly(A)+ tail. 134 However, this bias exists for all
amplified aRNA products and relative levels of gene expression can be compared. 134 The
optimized Eberwine RNA amplification method can amplify mRNA up to 103-fold after one
round and up to 105-fold after two rounds of amplification. 135-137 Therefore, approximately 10 ng
of input total RNA is necessary for successful microarray hybridization. 138 The number of cycles
of amplification can be increased to raise yield and it has been reported that a linear relationship
between transcript abundances is maintained after five cycles of RNA amplification. 139 Recently,
however, optimized methods based on the Eberwine method have been developed by a number
of different companies that have allowed for starting RNA amount in the picogram range.1
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Another method of amplifying RNA uses the polymerase chain reaction (PCR). This has
potential for high yield and simpler experimental procedures. 115 A number of different groups
have tried to amplify RNA this way.134,146-153 However, PCR-based amplification methods can
skew the original quantitative relationships between genes from an initial population.134 Some
groups have attempted to combine PCR and IVT to increase fidelity because only a limited
number of PCR cycles are used. 154 The suitability of PCR RNA amplification for microarry
analysis depends on a number of factors, including: 1) degree of fidelity 2) degree of coverage
by microarrays and 3) polarity of probes. 115
While most RNA amplification methods require purified total input RNA, it has been shown that
cell lysates can be directly amplified successfully.' 55 The use of cell lysates has the advantage of
not risking the loss of RNA during purification and, therefore, is amenable to amplifying RNA
from very limited numbers of cells.
Gene expression analysis
Two microarray platforms are available for studying virus epitope-specific CD8+ T cells from
rhesus monkeys. The first is the Illumina Beadchip platform, which consists of microscopic
beads with hundreds of thousands copies of 50-mer probes. The human BeadChips target more
than 25,000 annotated genes with more than 48,000 probes covering the RefSeq (Build 36.2, Rel
22) and the UniGene (Build 99) databases. Anywhere from 6 to 12 arrays can be run
simultaneously on the same BeadChip and starting unamplified RNA requirements are between
50 ng and 100 ng. The second platform is the Affymetrix GeneChip platform, which consists of
1.3 million oligonucleotides synthesized using photolithography on a glass substrate.
Affymetrix recently developed a Rhesus Macaque Genome Array with 52,024 probes sets of 25-
mer probes that query 47,000 rhesus monkey transcripts. Microgram amounts of starting RNA
are required for the Affymetrix arrays.
Materials and Methods
Animals
All animals used in this study were Indian-origin rhesus monkeys (Macaca mulatta). The
monkeys were all chronically infected with SIVmac251 for over ten years. These animals were
maintained in accordance with the guidelines of the Committee on Animals for the Harvard
Medical School and the Guide for the Care and Use of Laboratory Animals.
Antibodies, tetramers, and peptides
Mamu-A*01/pllC,C-M/B2m (SIVmac Gag) tetramer complexes were prepared as previously
described. 156' ,1 7 Streptavidin-PE (ProZyme) was mixed stepwise with biotinylated Mamu-
A*01/peptide at a molar ratio of 1:4 to produce the tetrameric complexes. Conjugated antibodies
used in this study included anti-human anti-CD3 APC (Clone SP34.2; BD-Pharmingen). The
anti-human anti-CD8 (clone SKI; BD-Pharmingen) monoclonal antibody was directly coupled to
fluorescein isothiocyanate (FITC). A live/dead fixable blue amine dye (UV excitation;
Invitrogen) was used to differentiate between live and dead cells on the flow cytometer.
Peripheral blood mononuclear cell (PBMC) preparation
Peripheral blood was collected from rhesus monkeys, and PBMCs were recovered by standard
Ficoll density-gradient centrifugation. The recovered cells were then washed twice with PBS
containing 2% FBS. Cells were stained with Mamu-A*01/pl C,C-M/B2m tetramer for 15 min
at 4oC in the dark. Cells were then stained with a mixture of anti-CD3 and anti-CD8 Abs for 10
min at 4oC in the dark. The cells were washed with PBS/2%FBS and resuspended in 1 ml of
cold PBS for every 107 cells. The pl 1C+ CD8+ T cells were sorted using the FACS-Vantage
Flow Cytometer/Cell Sorter (Becton-Dickinson) and collected in RNAprotect (Qiagen).
Cell extraction from Gastrointestinal Tract biopsies
Pinch biopsies (8-10 pieces) were taken from the duodenum and distal colon of anesthetized
monkeys at the New England Primate Center. The biopsies were shipped on ice in 40 ml RPMI
containing 10% FBS and were processed the same day. The biopsies were pelleted at 1,500 rpm
for 7 min. The supernatant was discarded and the biopsies were dissected further into smaller
sections before being resuspended in 40 ml warm RPMI/10%FBS containing 300 U/ml
Collagenase II and 30 U/ml DNAse I. The mixture was shaken well and placed in a shaking
37oC water bath for exactly 45 min, with manual shaking every 15 min. The digested biopsies
were then spun down at 1,500 rpm for 7 min, the supernatant was discarded, and 5ml of cold
RPMI/10%FBS was added to the sample. The tissue was disrupted through an 18G animal
feeding needle (Fisher Scientific) several times to release the cells and transferred through a
70 tm cell strainer into a clean 50 ml conical. The cell strainer was washed with an additional
45 ml of RPMI/10%FBS. The cells were spun down at 2,000 rpm for 5 min, the supernatant was
discarded, and the cells were resuspended in 10 ml RPMI/10%FBS. The cell mixture was
layered gently over a percoll gradient consisting of 2 ml of 35% isotonic Percoll underlaid with 2
ml of 60% isotonic Percoll (Sigma). Isotonic Percoll was made by adding 50 ml 10X PBS to
450 ml Percoll. The cells were centrifuged for 25 min at 1,800 rpm and the lymphocytes were
collected from the layer between the 35% and 60% Percoll layers and transferred to a fresh tube.
The collected lymphocytes were washed twice in cold PBS2%FBS at 2,000 rpm for 5 min and
counted. The cells were stained with a live/dead fixable blue amine dye (Invitrogen), incubated
for 15 min at 4oC in the dark. After washing with PBS/2%/FBS, the cells were then stained with
Mamu-A*01/pl 1C,C-M/B2m tetramer for 15 min at 4oC in the dark. They were washed once
with PBS2%FBS and then stained with a mixture of anti-CD3 and anti-CD8 Abs for 10 min at
4oC in the dark. The cells were washed with PBS/2%FBS and resuspended in 1 ml of cold PBS
for every 107 cells. The pllC+ CD8+ T cells were sorted using the FACS-Vantage Flow
Cytometer/Cell Sorter (Becton-Dickinson) and collected in RNAprotect (Qiagen) if the RNA
was to be extracted immediately. For cells that would be frozen immediately for freeze/thaw
lysis direct into RNA amplification, the cells were collected in 100 ul PBS in 96 well plates and
transferred to eppendorf tubes to be frozen at -800 C.
Cell extraction from bronchoalveolar lavage (BAL)
Bronchoalveolar lavage on rhesus monkeys was performed under anesthesia at the New England
Primate center. The samples were shipped on ice and processed the same day. PBMCs were
recovered by standard Ficoll density-gradient centrifugation. The recovered cells were then
washed twice with PBS containing 2% FBS and counted. The cells were stained with a live/dead
fixable blue amine dye (Invitrogen), and incubated for 15 min at 4C in the dark. After washing
with PBS/2%/FBS, the cells were stained with Mamu-A*01/pl 1C,C-M/B2m tetramer for 15 min
at 4C in the dark. They were washed once with PBS2%FBS and then stained with a mixture of
anti-CD3 and anti-CD8 Abs for 10 min at 40C in the dark. The cells were washed with
PBS/2%FBS and resuspended in 1 ml of cold PBS for every 107 cells. The pl 1C+ CD8+ T cells
were sorted using the FACS-Vantage Flow Cytometer/Cell Sorter (Becton-Dickinson) and
collected in RNAprotect (Qiagen) if the RNA was to be extracted immediately. For cells that
would be frozen immediately for freeze/thaw lysis direct into RNA amplification, the cells were
collected in 100 ul PBS in 96 well plates and transferred to eppendorf tubes to be frozen at -80'C.
RNA Extraction
Cells collected in RNAprotect (Qiagen) were spun down at 800 g for 10 min, discarding the
supernatant. Cells collected in PBS were spun down 1,500 rpm for 7 min, discarding the
supernatant. The appropriate lysis buffer was immediately added. RNA was extracted from the
cells according to manufacturer instructions for the Arcturus PicoPure Kit (MDS Analytical
Technologies), the RNeasy Micro Kit (Qiagen), or Trizol (Invitrogen).
Briefly, using the Arcturus PicoPure Kit, 100 ul of Extraction Buffer was added to the cells and
incubated at 42oC for 30 min. The cells were spun down and the supernatant was transferred to a
new tube. Equal volume of 70% ethanol was added and the mixture was transferred to a
purification column. Two wash buffers were used to wash through the column, along with a 15
min Dnase treatment step at room temperature. The RNA was then eluted with 11 ul of Elution
Buffer and stored at -80'C.
Using the RNeasy Micro Kit, 350 ul RLT Buffer containing 10 ul/ml of B-Mercaptoethanol was
added to the cells. The lysate was spun through a Qiashredder and then mixed with 70% ethanol
and placed in an RNeasy MinElute spin column. The column was washed with Buffer RW1,
followed by a Dnase I treatment for 15 min at room temperature. The column was washed with
buffer RW1, Buffer RPE, and 80% ethanol before the RNA was eluted in 14 ul of RNase-free
water. The RNA was stored at -800C.
Using the Trizol procedure, 1 ml of Trizol was added to the cell pellet and incubated for 5 min at
room temperature. Two hundred microliters of chloroform was added and shaken vigorously by
hand for 15 seconds, and incubated at room temperature for 2-3 min. The samples were then
centrifuged at 13,000 rpm for 15 min at 40C. The colorless upper aqueous phase was carefully
transferred to a new tube, and 2 ul of linear acrylamide was added and mixed in. An equal
volume of isopropyl alcohol was then added and mixed. The mixture was incubated at room
temperature for 10 min and centrifuged at 13,000 rpm for 10 min at 40C. The supernatant was
removed and the RNA was washed with 1 ml of 70% ethanol and centrifuged at 10,500 rpm for
5 min at 40C. The supernatant was completely removed and the RNA pellet was allowed to
airdry. The RNA was then resuspended in RNase-free water and stored at -800C.
RNA Amplification
RNA was amplified from purified total RNA or cell lysates using the TargetAmp 2-Round
Biotin-aRNA Amplification Kit 3.0 (Epicentre Biotechnologies) or the MessageAmp II aRNA
Amplification Kit (Ambion). For cell lysates, the frozen cells post-FACS sort were thawed
rapidly and then a portion of the lysate was input into the amplification procedure. Briefly, both
methods go through two rounds of cDNA synthesis and in vitro transcription (IVT). Both prime
the first strand cDNA synthesis with a T7-Oligo(dT) primer. For the Epicentre method, the first
strand cDNA synthesis is catalyzed by either Superscript II or III Reverse Transcriptase
(Invitrogen). The double stranded cDNA is synthesized by a DNA polymerase and the IVT is
catalyzed by a T7 polymerase. The first round IVT runs for 4 hours and the 2 nd round IVT
rounds for 9 hours, with biotin-UTP added in the 2nd IVT. RNA purification is performed using
the Zymo RNA Clean and Concentrator (Zymo Research) between the first and second rounds of
amplification and the RNeasy MinElute Cleanup Kit (Qiagen) after the second round of
amplification. For the Ambion MessageAmp Kit, the first strand cDNA synthesis is catalyzed by
ArrayScript (Ambion). Both IVT reactions last for 14 hours, with the biotin-NTPs added in the
2"d round IVT. In addition to the RNA purifications between rounds and after the final IVT,
there are also two cDNA purification steps after 2n d strand cDNA synthesis for each round.
Microarray processing
Amplified aRNA was hybridized to the Illumina HumanWG-6 v3.0, HumanRef-8 v3.0, or
HumanHT-12 Expression BeadChips according to the manufacturer's instructions (Illumina, San
Diego, CA, USA). The HumanWG-6 v3.0 BeadChip assays 48,000 transcripts and profiles six
samples simultaneously. The HumanRef-8 BeadChip targets approximately 24,500 well-
annotated RefSeq transcripts profiles eight samples in parallel. The HumanHT-12 BeadChip has
the same panel of probes as the HumanWG-6 v3.0 BeadChip but can process 12 samples in
parallel. The Beadchips contain content derived from the National Center for Biotechnology
Information Reference Sequence (NCBI RefSeq) database (Build 36.2, Release 22). Arrays
were scanned with an Illumina bead array reader confocal scanner, according to the
manufacturer's instructions. Array data processing was performed using Illumina BeadStudio
software.
Bioinformatic analysis comparing amplification protocols
The goal of this study was to compare the effects of these methods on the variability of the
results. Human Brain RNA (Ambion) in different starting amounts was amplified using either
TargetAmp 2-Round Biotin-aRNA Amplfication Kit 3.0 (Epicentre Biotechnologies) or the
MessageAmp II aRNA Amplification Kit (Ambion). Triplicates of each sample were provided
and the aRNA was hybridized to the Illumina HumanHT-12 BeadChip. The total number of
probes is large (nearly 50,000) and there is the danger of having the noise overwhelm the signal
if all the probes are compared at the same time. Therefore, a subset of probes (30 at a time) was
sampled to identify differences in the variability of the methods. To compare the variability, a
regression model was constructed. This model broke down the gene expression into two
components: the average contribution from each gene, and the average contribution from each
method. If the two amplification methods are quite different, the difference between their
contributions can be expected to be large. The p value is determined using a t-test. This sampling
is repeated and the procedure is tested 1,000 times, giving 1,000 p-values. From these p-values,
the overall p-value for the difference can be estimated. To assess the overall p-value, the median
p-value is taken to get a robust summary measure. To test the difference in amplifications, arrays
402, 403, and 461 were used to represent the Ambion amplification, and arrays 407, 408, 412,
and 413 were used to represent the Epicentre amplification (Fig. 3.3). These arrays all used
aRNA amplified from 100 pg of starting RNA.
Results
Selection of gene expression platform
Two gene expression platforms were investigated: the Affymetrix GeneChip Rhesus Macaque
Genome Array and the Illumina Human Beadchip. The two platforms were tested for sensitivity
and reproducibility for assessing gene expression levels in rhesus monkey lymphocytes. Using
RNA samples derived from peripheral blood mononuclear cells of 2 normal rhesus monkeys, the
Illumina Human BeadChip had better reproducibility than the Affymetrix GeneChip. The
reproducibility between the two samples was 46% for the Affymetrix GeneChip and 98% for the
Illumina Human BeadChip. Illumina Human BeadChips also required less starting RNA,
needing only 50 ng according to manufacturer specifications. Affymetrix technology requires
microgram levels of starting RNA.
The divergence of the human and rhesus genomes did not present a problem in the use of the
Illumina technology for this application. There is significant homology between the human and
rhesus genome, so differences at the protein or exonic DNA level should be small. In fact, a
pilot experiment hybridizing human samples on the Illumina Human BeadChip resulted in the
detection of 10,000-11,000 expressed genes while a rhesus monkey sample on the Illumina
Human BeadChip resulted in the detection of 7-8,000 expressed genes. The same rhesus
monkey sample placed on the Affymetrix Rhesus GeneChip also resulted in the detection of
7,000 expressed genes. For the reasons of superior reproducibility, less required starting RNA,
and adequate homology, the Illumina Human BeadChip was chosen as the gene expression
platform for future studies.
RNA requirement for Illumina platform
To determine the minimum amount of unamplified total RNA required for the Illumina Beadchip
to generate clear and reproducible data, limiting dilutions of total RNA were tested on the
Illumina Beadchip (all done on Human-8 v2 Beadchip except for the 100ng sample which was
run on the Human-6 v2 chip). R squared values as well as numbers of genes present are shown
for different starting quantities of RNA (Table 3.1).
Table 3.1. Numbers of genes detected and R squared values for limiting dilutions of total
RNA on Illumina Human BeadChip. All samples were hybridized to Illumina Human-8 v2
Beadchips except for the 100 ng sample which was hybridized to the Human-6 v2 chip.
RNA Amount (ng) Genes Detected R Squared
100 8000 0.998
50 6000 0.995
25 6000 0.995
10 4900 0.99
5 4300 0.97
The results show that as low as 25 ng of starting unamplified RNA can be used on the Illumina
Human BeadChip without a significant decline in R squared values.
RNA Extraction from limited cell numbers
With 25 ng of total RNA as a target, methods for extracting high yield and high integrity RNA
from epitope-specific CD8+ T lymphocytes were investigated. A number of protocols were
tested, including the Qiagen RNeasy Micro Kit, the Arcturus PicoPure Kit, and the traditional
phenol/chloroform Trizol procedure. Our results showed that the Trizol method consistently
provided the highest RNA yield and the RNeasy Micro Kit provided the highest RNA integrity.
While high integrity RNA is of paramount importance for down-stream chip analysis, we have
never been able to extract detectable RNA from fewer than 10,000 epitope-specific CD8+ T cells
using RNeasy Micro Kit. From mucosal samples, 100 to 600 epitope-specific CD8+ T
lymphocytes are typically isolated, well below the limit for the Rneasy Micro kit. Therefore, it
was decided that the Trizol method was the best available option. The Trizol procedure was
therefore optimized further to obtain detectable and high integrity RNA.
Extraction of RNA from small numbers of cells was successfully achieved using the Trizol
method. From blood-derived epitope-specific (pl 1C+) CD8+ T lymphocytes, RNA with a high
RNA integrity number (RIN>7) as measured by Agilent Bioanalyzer was obtained from 10,000,
1,000, 800 and 600 FACS-sorted p1 1C+ CD8+ T lymphocytes (Fig. 3.1).
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Figure 3.1. Quantity and RNA integrity of Trizol extracted RNA from limiting dilutions of
FACS sorted pllC+ CD8+ T cells. All cells were resuspended in 10 ul RNase-free water. (A)
10,000 pl 1C+ cells (B) 1,000 pll 1C+ cells (C) 800 pl1 C+ cells (D) 600 pl 1C+ cells.
However, regardless of extraction method, 25 ng of purified RNA is more than can be obtained
from fewer than 500 epitope-specific CD8+ T lymphocytes. Therefore, RNA amplification is
necessary to obtain sufficient amounts of RNA for Illumina Beadchip analysis.
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Selection of RNA amplification method
In order to be compatible with the Illumina platform, total RNA must be amplified and
transformed to aRNA (antisense RNA). There are two commercially available kits that provide
two rounds of RNA amplification with a transformation to biotin-aRNA during the second
amplification. They are the Epicentre TargetAmp 2-Round Biotin-aRNA Amplification Kit 3.0
and the Ambion MessageAmp II aRNA Amplification Kit.
The Epicentre Kit can amplify from a minimum of 10 pg of starting RNA to a maximum of
500 pg of starting RNA. The reaction is primed from a T7-Oligo(dT) primer and goes through
two separate rounds of cDNA synthesis and in vitro transcription. The Ambion MessageAmp
Kit works with a minimum of 100 pg and a maximum of 100 ng starting RNA for the 2-round
amplification. Like the Epicentre Kit, the RNA is also primed from a T7-Oligo(dT) primer and
goes through two rounds of cDNA synthesis and in vitro transcription. Some of the enzymes and
reagents are different between the two kits as well as some of the manipulations.
The Epicentre and Ambion kits were first compared for aRNA yield and quality. Yield was
determined using the Nanodrop ND1000 and RNA quality was determined with both the Agilent
Bioanalyzer and Illumina Human Beadchip analysis, looking at the RNA Integrity Number
(RIN) in the former and the number of expressed genes and hybridization controls in the latter.
Both methods yielded similar amounts of aRNA from 100 pg of starting RNA (Table 3.2). Both
amplification protocols also produced aRNA of appropriate and similar lengths (250-5000 nt in
length; data not shown).
Table 3.2. aRNA yields from Ambion Message Amp II aRNA Amplification Kit (with 2
rounds) and Epicentre 2 Round Amplification Kit. Ambion human brain control RNA was
used.
Starting RNA amount aRNA Yields
(nanogram) Ambion Kit Epicentre Kit
100 548ug N/A
0.5 N/A 31ug
0.1 6.5ug 8.8ug
No RNA control 648 ng 617ng
To investigate the hybridization quality and gene expression signal of aRNA products amplified
by the two different methods, triplicates of amplified aRNA were processed from each starting
RNA amount. For the Ambion MessageAmp Kit, we used the recommended amount of starting
RNA (100 ng) as well as the minimum amount of starting RNA (100 pg). For the Epicentre kit,
we used the maximum allowed amount of starting RNA (500 pg) as well as 100 pg starting RNA
to match the set amplified by the Ambion Kit. All the samples, as well as negative controls
(containing no starting RNA), were hybridized to Illumina Human-12 BeadChips and analyzed
as described in the methods section.
Comparing the 100 pg triplicates amplified using the Ambion or Epicentre methods, there was
no statistically significant difference between the two methods, giving a p value of 0.37 (Fig.
3.2).
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Figure 3.2. Histogram of p-values comparing Ambion versus Epicentre amplified aRNA. P
value is 0.37.
The values for the samples were highly correlated (Fig. 3.3). The identification numbers along
the diagonal in Fig. 3.3 are described by the key to the left of the figure: 398, 455, and 458 are all
Ambion amplified samples from a starting RNA amount of 100 ng, and so on. Correlation
within platforms for final RNA quantities starting with the same RNA amounts was consistently
above 0.9, with the exception of sample 461. This outlier value possibly represents an error
during processing. The correlations among arrays 398, 455, and 458 (all Ambion amplified from
100ng starting RNA) were nearly perfect (0.99 to 1). This suggests that as the starting RNA
amount increases, the reproducibility of gene expression profiles across samples should increase.
Comparing across amplification methods, but with the same starting RNA amount (100 pg), the
correlation is still fairly strong with values between 0.86 and 0.88 (with the exception of sample
461). Lastly, comparing within the same amplification method but between different starting
RNA amounts, the correlation is also fairly robust, with values greater than 0.9 for most pairs.Og
RNA amounts, the correlation is also fairly robust, with values greater than 0.9 for most pairs.
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Figure 3.3. Scatterplots and correlation coefficients of pairs of aRNA samples amplified
with the Ambion or Epicentre methods and starting from different RNA amounts. Sample
identification numbers lie on the diagonal and are described by the key to the left of the figure.
These results are further corroborated by the profile of the number of genes expressed in each
sample (Fig. 3.4). Sample 461 is again an outlier with many fewer expressed genes than the
other samples. The number of expressed genes also decreases modestly as the starting RNA
amount decreases.
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From the above analysis, it is apparent that the two amplification methods provide equivalent
data. There is, however, a time advantage to using the Epicentre Kit, since it takes one day less
to process the samples. Therefore, the decision was made to use the Epicentre TargetAmp 2-
Round Biotin-aRNA Amplification Kit 3.0 for amplifying future RNA samples.
Purified RNA versus cell lysates for amplification
Obtaining high quality purified RNA from limited cell numbers (less than 1,000 cells) remains a
challenge. Measurable high quality RNA cannot be obtained from less than 1,000 cells
consistently. Therefore, the possibility of using cell lysates without RNA purification in the
amplification process is being investigated. A preliminary experiment to check the feasibility of
using cell lysates was conducted.
One thousand monkey peripheral blood mononuclear cells (PBMCs) were frozen at -80'C in
20 ul of phosphate buffered saline (PBS) and then lysed by quick thaw at room temperature with
an addition of 1 ul of RNase Inhibitor. One microliter of the thawed cell lysate was then input
into the Epicentre 2-round amplification procedure. At the end of two rounds of amplification,
10.3 ug of aRNA was obtained. The aRNA had good Nanodrop ratios (A260/A280 between 1.8
and 2), and good Agilent Bioanalyzer readouts (product lengths corresponding to between 250 nt
and 5000 nt) (Fig. 3.5 and 3.6). A purified RNA sample (Hela control) was amplified for
comparison.
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Figure 3.5. Nanodrop reading for amplified aRNA from Hela control and 1 ul of lysate
from 1,000 normal monkey peripheral blood mononuclear cells (PBMCs). The aRNA
samples were resuspended in 40 ul of Rnase-free water.
H C
RIN: 2.10 Hela control aRNA : 7.90 Cell lysate aRNA
:FU] [FU:
100 5-
50-50
50 i/
30 40 50 60 70 80 [s] 20 25 30 35 40 45 50 55 60 65 [s:
Figure 3.6. Agilent Bioanalyzer readouts for amplified aRNA for Hela control and 1 ul of
cell lysate from 1,000 monkey PBMCs.
A SYBR Green-based real time quantification of GAPDH was then performed on the aRNA
from both the cell lysate and the Hela control and showed successful detection of GAPDH after
17 cycles for the cell lysate derived aRNA and after 21 cycles for the Hela control aRNA (Fig.
3.7).
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Figure 3.7. SYBR Green QPCR of GAPDH on amplified cell lysate from monkey PBMCs
as well as Hela and control RNAs. (A) Amplification curves for GAPDH gene. (B)
Dissociation curves for GAPDH gene.
Given these initial positive results, the feasibility of amplifying lysates from sorted cells was
assessed. Epitope-specific (pl1 C+) CD8+ T cells from monkey peripheral blood and mucosal
biopsies were collected by FACS sorting and the cells were either lysed directly or the RNA was
extracted from them using Trizol. From mucosal cells, only lysates of pl1 C+ CD8+ T cells
were tested due to limiting cell numbers. Adequate yields of aRNA were obtained from both the
purified RNA and the cell lysates (Table 3.3 and Fig. 3.8), with lysates giving higher yields than
purified RNA at higher cell numbers and purified RNA giving higher yields than lysates at lower
cell numbers.
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Table 3.3. Comparison of aRNA yield from purified RNA and cell lysate from mucosal and
blood pllC+ CD8+ T lymphocytes. (P) = Purified RNA. (L) = Cell lysate.
ID Sample Description aRNA amount (ug)
1 Hela control 77
4 Duodenum (L) 18
8 Colon (L) 13
6 1000 Blood cells (P) 15
2 1000 Blood cells (L) 32
7 800 Blood cells (P) 15
9 800 Blood cells (L) 10
3 600 Blood cells (P) 24
5 600 Blood cells (L) 17
10 No RNA Control 0.2
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Figure 3.8. Comparison of aRNA yield from purified RNA and cell lysate from mucosal
and blood pllC+ CD8+ T lymphocytes. The numbers along the curves correspond to the ID
numbers in Table 3.3.
However, simply looking at yield is not sufficient. The most important consideration is how
well the samples perform on the Illumina Human BeadChip. To create enough statistical power,
to make this evaluation useful, two biological replicates (PBMCs from 2 chronically SIV-
infected rhesus monkeys), and triplicates of purified RNA or cell lysates at limiting cell number
dilutions were generated. All samples were amplified using the Epicentre TargetAmp 2-Round
Biotin-aRNA Amplification Kit 3.0 and hybridized to the Illumina Human BeadChip. Once a
reproducibility and repeatability analysis can be conducted, the feasibility of using cell lysates
for amplification and gene expression analysis will be assessed. The experimental results are
pending. Once the decision is made, the entire gene expression assay will be complete (Fig. 3.9).
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Figure 3.9. Schematic of gene expression profiling assay for epitope-specific CD8+ T
lymphocytes.
Discussion
The Trizol method gave higher yields of purified RNA from limiting numbers of cells than the
RNeasy Micro Kit, or the Arcturus PicoPure Kit. Trizol extracted RNA was also of high
integrity (Fig 3.1) and can be amplified successfully using the Epicentre TargetAmp 2-Round
Biotin-aRNA Amplification Kit 3.0 (Fig. 3.8). The Trizol method does not employ a column,
which enhances the final RNA yield. This method may lead to contamination with organics that
can be detrimental to the assays that will be employed to analyze the RNA. Therefore, this
method requires careful attention to avoid contaminants in the isolated RNA.
The Epicentre TargetAmp 2-Round Biotin-aRNA Amplification Kit 3.0 and the Ambion
MessageAmp II aRNA Amplification Kit yielded comparable quantities of high quality aRNA.
These kits had comparable reproducibility and generated comparable gene expression analyses
(Figs. 3.2 and 3.3). While amplification is necessary to investigate the gene expression profile of
rare cell populations, the process of amplification can also bias the profile. The linear
amplification methods used by both Epicentre and Ambion minimize bias. Nevertheless,
amplified samples can only be compared with other similarly amplified samples and not with
unamplified samples.
The direct amplification of cell lysates can be used for gene expression analysis of as few as tens
of cells. However, the mRNA in lysates of cells contains contaminants and therefore, the
amplification efficiency will not be perfect. An oligo-dT primer must sift through a large
quantity of cellular matter to bind the mRNA. Because of this, it is possible that some of the
mRNA in those cells will be 'lost in the mix' and will not be amplified. Therefore, there is a
chance that the gene expression profile generated will be limited. In addition, there are proteases
in the cellular matter, including RNases. It is essential that any RNases be eliminated
immediately upon thawing the cells. Otherwise, as noted previously, some of the mRNA will be
degraded and therefore not available for amplification.
The Illumina Human BeadChip platform is precise, reproducible, and cost effective, and can run
many samples in parallel. However, the BeadChip is a human chip and therefore, will not have
identical homology to the rhesus monkey genome. While homology is great enough for our uses,
looking forward, it may be worthwhile to custom design an Illumina BeadChip to match the
rhesus monkey genome.
CHAPTER 4: Gene expression profile of peripheral blood SIV
Gag epitope-specific CD8+ T lymphocytes during primary SIV
infection in Mamu-A*01+ and Mamu-A*02+ rhesus monkeys
Introduction
Emerging data suggest that CD8+ cytotoxic T cells can contribute substantially to early virus
control. Kuroda et al. showed that the emergence of SIV-specific CD8+ cytotoxic T cells
coincides with a decrease in viral loads.24 Schmitz et al. showed that upon depletion of CD8+
cytotoxic T cells, early control of SIV fails.25 Viral loads also increase in chronic SIV infection
upon CD8+ T cell depletion. 26'27 In addition, the evolution of viral mutants in vivo is
characterized by mutations that cause the virus to evade recognition by CD8+ cytotoxic T cells. 3
Previous studies have indicated an association between the expression of the MHC class I allele
Mamu-A*01 and a reduction in plasma virus RNA levels in monkeys infected with
SIVmac239158'159 and SIVmac251,16'0,161 and lower lymph node-associated virus concentrations
in SHIV-89.6P infections.162 SIV-infected A*01+ rhesus monkeys have one or more logs lower
plasma virus RNA levels than A*01- monkeys. Because A*01 is a class I MHC molecule, CD8+
T cells likely play a role in the control of viremia in these monkeys.To test this hypothesis,
blood-derived SIV-specific CD8+ T cells from A*01+ (A*02-) and A*02+ (A*01-) monkeys can
be studied temporally using different functional and genomic assays.
Previous studies have also shown that Mamu-B*17 and Mamu-B*08 are associated with superior
SIV viral control. 159',163 164 To abrogate the possible confounding effects of these two alleles,
monkeys will be chosen based on their B*08- B*17 status. Several virus epitope-specific CD8+
T lymphocyte populations can be sorted and analyzed specifically, including the dominant Gag-
pl1 C and Tat-TL8 specific CD8+ T cells and the subdominant Env p54AS (or Env TL9) specific
CD8+ T cells from A*01+ monkeys and the dominant Nef-p199RY specific CD8+ T cells from
A*02+ monkeys.
2'156
,165-170
While virus-specific CD8+ memory T lymphocyte differentiation in the setting of viral infections
has been intensively studied in murine models,171-174 limited work has been done in this area in
non-human primate/SIV models. HIV-1 and its non-human primate counterpart SIV are different
from other chronic infections because of the persistence of viremia and loss of CD4+ T cell help.
Therefore, we might expect the evolution of CD8+ T lymphocytes to differ in the setting of SIV
infections from that of other chronic persistent viral infections.
Gene expression studies of T cells have evaluated naive, effector, and memory T cells, resting
versus activated T cells, and T cells undergoing homeostatic proliferation.44,46' 174-178 Results
suggest a coordinated progression of lymphocyte gene expression changes following activation
and suggest that trafficking of T cells is inhibited early during T cell activation." The genetic
program of naive, effector, and memory T cell specific for LCMV in mice was studied by several
groups.172-174 Looking primarily at genes involved in effector and regulatory functions, in cell
cycle control, and in susceptibility to apoptosis, naive CD8+ T cells had a gene signature of high
levels of lung Kruppel-like factor (LKLF) and the cyclin-dependent kinase inhibitor (CDKi) p27,
moderate levels of the anti-apoptotic Bcl-2 and pro-apoptotic Bax, and low levels of perforin,
IFN-,y, FasL, pro-apototic Bad, anti-apoptotic Bcl-xL, and the CDKi p21.173,175 Following
infection with LCMV, the cells changed to an effector phenotype and their genetic signature
evolved as well, exhibiting high levels of IFN-y, perforin, FasL, granzymes A,B, D, and K, and
RANTES, moderate levels of Bcl-2, and low levels of Bad, Bax, and Bcl-xL,. LKLF, p27, and
p21 levels decreased initially but increased again by day 8 following infection. 173 ,174 Genes
encoding chemotactic proteins, cell adhesion proteins, and P-selectin ligand were increased in
effector CD8+ T cells while lymph node homing proteins were reduced. 174 Signal transduction
genes involved in TCR signaling, intracellular Ca2+ signaling, and cytokine signaling were
expressed at higher levels. To counteract that with negative regulations of TCR and cytokine
signaling, PEP phosphatase and SOCS-5 expression was increased and IL-4, IL-7, and IFN-y
receptor a chain expression was decreased. 174 Genes regulating actin polymerization showed
increased expression, which can lead to increased cell motility and signaling, while genes
involved in protein translation showed decreased expression, which can contribute to effector
cell apoptosis. 174 After viral clearance, the antigen-specific CD8+ T cells entered the memory
phase and the genotype changed to one of high levels of IFN-y, Bcl-2, Bax, RANTES, MIP-113,
granzymes B, K, M, and LKLF, and decreased levels of Bcl-x p27 and p21.173 There were
mixed results on perforin and FasL, where one study showed lower expressionl 73 in memory T
cells, while another study showed higher levels. 174 This discrepancy may be due to differences in
the experimental conditions and differences between total CD8+ T cell populations' 74 versus the
focused antigen-specific CD8+ T cell population. 173 In addition, CXCR4 was selectively up-
regulated in memory CD8+ T cell, as were the GPI-linked proteins Ly-6C and Ly-6A/E,
members of the p38 and JNK signaling pathways, cyclin El, E2, and B1, and the IL-16Ra
chain. 174 In summary, approximately 350 genes were differentially expressed at least 1.7-fold in
either effector or memory CD8+ T cells as compared to naive cells, of which 30% were up-
regulated in both effector and memory CD8+ T cells. 174 This suggests that many of the
regulatory gene changes that occurred during the transition from naive to effector CD8+ T cell
were maintained in memory cells. 174 However, there were subsets of genes that were
differentially expressed between effector and memory CD8+ T cells, suggesting that they are two
distinct cell populations. 174 Temporal gene expression studies showed memory cell qualities
were acquired between days 8 and 22 post-infection. 174
The development of gene microarrays have provided investigators with a tool to measure subtle
changes in mRNA levels. 177 Affymetric gene array analysis of superantigen-activated T cells
showed expression of many genes associated with cycling cells such as those of the cyclins,
cyclin dependent kinases, and DNA polymerases, while resting T cells expressed a number of
cytokine receptor genes and genes thought to suppress cell division.' 75 Results also suggested
that the MAP kinase signaling pathway may be significantly dampened in activated T cells. 175
Activation, while changing the spectrum of genes expressed, did not change the diversity of
genes expressed. 175 Shortly after T cell activation, genes for interferon receptors and for Statl are
repressed. 177
Several studies have shown that cytotoxic T cells are impaired in function in the setting of
persistent viral infection, 179-181 while others have countered this by describing the preservation of
CTL function in chronic persistent viral infections, including HIV. 179,182 ,183 Gene expression
analysis of the virus-specific CD8+ T lymphocytes will shed new light on this question and
uncover mechanisms to explain the functional and phenotypic observations.
During chronic viral infections, CD8+ T cell responses often become dysfunctional and
sometimes virus-specific CD8+ T cells fail to differentiate into memory CD8+ T cell.
184
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During chronic LCMV infection, virus-specific CD8+ T cells gradually lose effector functions,
whereby IL-2, cytotoxity, and proliferation function are lost early and IFN-y persists longer. 186
If the virus load is high and CD4+ T cell help is absent, virus-specific CD8+ T cells can lose all
effector functions. 186,187 An important microarray study looking at gene expression profile
differences between CD8+ T cells in chronic viral infection versus acute viral infection in a
mouse LCMV model showed that exhausted CD8+ T cells over-expressed a number of
inhibitory receptors such as PD-1, LAG-3, and 2B4, down-regulated genes associated with TCR
signaling and cytokine receptors such as IL-7 and IL-15, and displayed altered expression of
genes involved in chemotaxis, adhesion, and migration. 8",1 85 There appeared to be perturbations
in the signaling apparatus available to communicate extracellular information via both the TCR
and cytokine receptors to the nucleus. 185 Exhausted CD8 T cells had many translational,
metabolic and bioenergetic deficiencies and also expressed a distinct set of transcription
factors. 185 There appeared to be perturbations in the signaling apparatus available to
communicate extracellular information via both the TCR and cytokine receptors to the
nucleus.' 85 This model of exhaustion may well apply to HIV-1 and SIV infections where the
virus persists and CD8+ T cell dysfunction develops. 3 -32,188
Materials and Methods
Animals
Six Mamu-A*01+ Mamu-A*02- Indian-origin rhesus monkeys (Macaca mulatta) and 6 Mamu-
A*02+Mamu-A*1O rhesus monkeys, all B*08- and B*17-, were selected for the study after PCR-
based MHC typing. They were challenged intra-rectally with 4.65 log RNA copies of
SIVmac251. These animals were maintained in accordance with the guidelines of the
Committee on Animals for the Harvard Medical School and the Guide for the Care and Use of
Laboratory Animals.
Antibodies, tetramers, and peptides
Mamu-A*01/pllC,C-M/B2m (SIVmac Gag), Mamu-A*01/TL8/B2m (SIVmac Tat), Mamu-
A*01/p54AS/B2m (SIVmac Env), Mamu-A*02/pl99RY/B2m (SIVmac Nef) tetramer
complexes were prepared as previously described. 15 6,157,165 Streptavidin-PE (ProZyme),
streptavidin-APC (ProZyme), and streptavidin-QDot655 (Invitrogen) were mixed stepwise with
biotinylated Mamu-A*01/peptide or Mamu-A*02/peptide complexes at a molar ratio of 1:4 to
produce the tetrameric complexes. Conjugated antibodies used in this study included anti-
CD247 Alexa488 (Clone K25-407.69; BD Product No. 558486), anti-phosphotyrosine PE (Clone
PY20; BD Product No. 558008), anti-CD3 APC (Clone SP34.2; BD-Pharmingen). The rest of
the antibodies used in this study were directly coupled to phycoerythrin (PE), allophycocyanin
(APC), fluorescein isothiocyanate (FITC), peridinin chlorophyll protein-Cy5.5 (PerCpCy5.5),
allophycocyanin-Cy7, ECD, and PECy7. The following monoclonal antibodies were used: anti-
CD8a (clone SKI; BD-Pharmingen), anti-CD3 (Clones SP34; BD-Pharmingen), anti-CD4
(Clone 19Thy5D7; in house production), anti-CD4 (Clone L200; BD-Pharmingen), anti-CD28
(Clone CD28.2; eBioscience), and anti-CD95 (Clone DX2; BD-Pharmingen).
Blood processing and cell staining
Peripheral blood was collected from the 12 rhesus monkeys at weekly intervals post-SIVmac251
challenge. In addition, blood was collected a week prior to infection and on the day of infection
(day 0) to establish baseline complete blood count (CBC) using the ADVIA 120 Hematology
System (Bayer) and expression profile measurements on total or naive CD8+ T cells in addition
to a baseline tetramer staining. For each timepoint, 10 ml of blood with EDTA was collected
and 850 ul of whole blood was saved for CBC analysis. The blood was then layered over 4ml of
Ficoll and spun at 3,000 rpm for 20 min. Plasma from the top layer was collected in 5 aliquots of
500 ul each and frozen at -80'C. Viral RNA was routinely isolated from 200 ul or 400 ul of cell-
free blood plasma following manufacturer's protocol. Using a qRT-PCR based method, viral
load was determined by comparing against a SIV RNA standard harboring the first 731 bp of the
SIVmac239-Gag Gene. PBMCs were recovered from the buffy layer and were washed twice
with PBS containing 2% FBS. For baseline measurements (pre-infection), cells were stained for
10 min at 4oC with a mixture of anti-CD4, anti-CD3, anti-CD8, anti-CD28, and anti-CD95
antibodies to stain for naive CD8+ T cells and a mixture of anti-CD4, anti-CD3, and anti-CD8 to
stain for total CD8+ T cells. On day 0 and weekly post-infection, cells were stained with Mamu-
A*01/pllC,C-M/B2m, Mamu-A*01/TL8/B2m, and Mamu-A*01/p54AS/B2m, or Mamu-
A*02/p199RY/B2m tetramers for 15 min at 40C. Cells were then stained with a mixture of anti-
CD3 and anti-CD8 Abs for 10 min at 40C. The cells were washed with PBS/2%FBS and
resuspended in 1 ml of cold PBS per every 107 cells. The pllC+ CD8+ T cells were sorted
using the FACS-Vantage Flow Cytometer/Cell Sorter (Becton-Dickinson) and collected in
RNAprotect (Qiagen).
RNA Extraction
RNA was extracted from the cell pellet using Trizol (Invitrogen). Briefly, 1 ml of Trizol was
added to the cell pellet and incubated for 5 min at room temperature. Two hundred microliters of
chloroform was added and shaken vigorously by hand for 15 seconds, and incubated at room
temperature for 2-3 min. The samples were then centrifuged at 13,000 rpm for 15 min at 40C.
The colorless upper aqueous phase was carefully transferred to a new tube, and 2ul of linear
acrylamide was added and mixed in. An equal volume of isopropyl alcohol was then added and
mixed. The mixture was incubated at room temperature for 10min and centrifuged at 13,000
rpm for 10 min at 40C. The supernatant was removed and the RNA was washed with lml of
70% ethanol and centrifuged at 10,500rpm for 5 min at 40C. The supernatant was completely
removed and the RNA pellet was allowed to airdry. The RNA was then resuspended in RNase-
free water and stored at -800C. To check for RNA integrity, 1 ul of the sample was tested using
an Agilent Bioanalyer.
RNA Amplification
RNA was amplified from Trizol extracted total RNA using the TargetAmp 2-Round Biotin-
aRNA Amplfication Kit 3.0 (Epicentre Biotechnologies). The amplification process provides
two rounds of cDNA synthesis and in vitro transcription (IVT). The first strand cDNA synthesis
is primed with a T7-Oligo(dT) primer and the first strand cDNA synthesis is catalyzed by either
Superscript II or II Reverse Transcriptase (Invitrogen). The double stranded cDNA is
synthesized by a DNA polymerase and the IVT is catalyzed by a T7 polymerase. The first round
IVT runs for 4 hours and the 2nd round IVT rounds for 9 hours, with biotin-UTP added in the 2 nd
IVT. RNA purification is performed using the Zymo RNA Clean and Concentrator (Zymo
Research) between the first and second rounds of amplification and the RNeasy MinElute
Cleanup Kit (Qiagen) after the second round of amplification. Amplified aRNA is resuspended
in RNase-free water and stored at -80'C. Samples that only need to be amplified one round were
amplified with the Illumina(R) TotalPrep(TM) RNA Amplification Kit (Ambion). Nanodrop
ND-1000 is used to determine RNA concentration and an Agilent Bioanalyzer is used to
determine aRNA integrity.
Microarray processing
Amplified RNA was hybridized to Illumina HumanHT-12 Expression BeadChips according to
the manufacturer's instructions (Illumina, San Diego, CA, USA). The HumanHT-12 BeadChip
has the same panel of probes as the Illumina HumanWG-6 v3.0 BeadChip, which assays 48,000
transcripts, but can process 12 samples in parallel. The BeadChips contain content derived from
the National Center for Biotechnology Information Reference Sequence (NCBI RefSeq) database
(Build 36.2, Release 22). Arrays were scanned with an Illumina bead array reader confocal
scanner, according to the manufacturer's instructions. Array data processing was performed using
Illumina BeadStudio software.
Results
Testing early activation after Mamu-A*01/p11C tetramer staining before and after sorting
In order to isolate virus epitope-specific CD8+ T cells, MHC class I tetramers are used to label
the cells and identify them for sorting. It is, however, possible that the tetramers may induce
TCR activation, which can alter the gene expression profiles of these cells. To test this, cells
were stained with antibodies specific for phosphorylation sites on the CD3 molecule (CD3 ) as
well as with Mamu-A*01/pl IC (SIVmac Gag) tetramer under various temperature conditions
and for varying incubation times. Figure 4.1 shows that long-term incubation on ice does not
appear to have any effect on phosphorylation of CD3 . However, Figures 4.2 and 4.3 show that
sorted cells that had been stained with tetramer exhibited high amounts of CD3 phosphorylation,
and thus activation. Simply staining the cells with tetramer on ice or at 37C did not induce as
much phosphorylation. Staining on ice induced the least amount of activation.
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Figure 4.1. Effect of long-term incubation of tetramer-stained cells on ice on
phosphorylation of CD3 . PBMCs were isolated using Ficoll density gradient. The positive
control was stimulated with anti-CD3 and anti-CD28, fixed, and stained for anti-pCD3 (light
green histogram to the far right). Unstimulated cells that were only stained with anti-pCD3
were also used as a negative control (orange histogram). A population of cells were not labeled
with tetramer and simply passed through the sorter (thick blue line to the far left). The remainder
of the cells were stained with Mamu-A*01/pllC on ice for varying amounts of times ranging
from 10 min to 2 hrs before fixing with BD Fix Buffer I and staining with anti-pCD3 .
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Figure 4.2. Staining with anti-phosporylated CD3 and fixing at 37°C. PBMCs from a
Mamu-A*01+ rhesus monkey were isolated by Ficoll density gradient. All samples were
fixed in BD Fix Buffer I (4% formaldehyde) at 37C for 10 min. The positive control
was stimulated with anti-CD3 and anti-CD28, fixed, and stained for anti-pCD3 (Blue
histogram). Alexa488 FMO was used as a negative control (Red histogram). Unstimulated
cells that were only stained with anti-pCD3 were also used as a negative control (Brown
histogram). Experimental cells were incubated with Mamu-A*01/pl C for either 3 min on
ice (orange histogram) or at 37oC (green histogram) and then fixed and permeabilized with BD
Fix Buffer I and stained with anti-pCD3 . The pl1C-sorted cells were stained with Mamu-
A*01/pllC for 15 min at 4oC, sorted by FACS Vantage, and fixed and permeabilized with BD
Fix Buffer I and stained with anti-pCD3 (Pink histogram).
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Figure 4.3. Staining with anti-phosporylated CD3 and fixing on ice. PBMCs from a
Mamu-A*01+ rhesus monkey were isolated by Ficoll density gradient. All samples with
the exception of the negative control (Alexa488 FMO) were fixed in BD Fix Buffer I (4%
formaldehyde) on ice for 1 hr. The positive control was stimulated with anti-CD3 and
anti-CD28, fixed, and stained for anti-pCD34 (dark green histogram). Alexa488 FMO was
used as a negative control (Red histogram). Unstimulated cells that were only stained with anti-
pCD3 were also used as a negative control (light green histogram). Experimental cells
were incubated with Mamu-A*0l/pllC for either 3 min on ice (light blue histogram) or at
37oC (dark blue histogram) and then fixed and permeabilized with BD Fix Buffer I and stained
with anti-pCD3 . The pllC-sorted cells were stained with Mamu-A*0l/pllC for 15 min at
4°C, sorted by FACS Vantage, and fixed and permeabilized with BD Fix Buffer I and stained
with anti-pCD3 (brown histogram).
CD8+ T cell isolation from peripheral blood and RNA extraction for baseline
measurements
For use as baseline comparators, total CD8+ T cells and naive CD8+ T cells were
isolated one week prior to challenge and on the day of challenge pre-infection from
peripheral blood using FACS. The sorting schematic is shown in Figure 4.4 using a
representative set of Mamu-A*01+ and Mamu-A*02+ monkeys.
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Figure 4.4. Schematic for sorting total and naive CD8+ T cells for baseline measurements.
From A*01+ Mm107-2006, 150,000 naive CD8+ T cells and 280,000 total CD8+ T cells
were collected. From A*02+ Mm337-2008, 900,000 naive CD8+ T cells and 1,145,000
total CD8+ T cells were collected.
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From the FACS isolated total and naive CD8+ T cells, high quality RNA with RNA
Integrity Numbers (RIN) greater than seven as measured by an Agilent Bioanalyzer were
extracted using the Trizol method (Fig. 4.5).
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Figure 4.5. RNA integrity and quantity from baseline total and naive CD8+
Mm107-20076 (A*01+) and Mm337-2008 (A*02+) pre-challenge on Day 0.
extracted using the Trizol method. Analysis was done by Agilent Bioanalyzer and
were resuspended in 10 ul RNase-free water.
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Isolation of SIV Gag epitope-specific CD8+ T cells from peripheral blood and RNA
extraction
Weekly following SIVmac251 intra-rectal challenge, 10 ml of blood was obtained from each
monkey and virus epitope-specific CD8+ T cells were isolated using FACS. From the Mamu-
A*01+ monkeys, Mamu-A*01/pllC, Mamu-A*01/TL8, and Mamu-A*01/p54AS were isolated
and collected in RNAprotect. From the Mamu-A*02+ monkeys, Mamu-A*02/pl99RY tetramer
positive cells were collected. The sorting schematic used is shown in Figures 4.6 and 4.7.
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Figure 4.6. Tetramer cell sorting for Mm107-2006 (A*01+) on Day 14 post SIVmac251
intra-rectal challenge. Gating schematic is shown above, selecting for singlets, then
lymphocytes, then CD3+CD8+ T cells. Mamu-A*01/pllC, Mamu-A*01/TL8, Mamu-
A*01/p54AS, Mamu-A*02/pl99RY tetramer positive cells were sorted in parallel into FACS
tubes filled with RNAprotect Reagent. A total of 89,000 pl 1C+ cells, 270,000 TL8+ cells, and
1,000 p54AS+ cells were collected.
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Figure 4.7. Tetramer cell sorting for Mm337-2008 (A*02+) on Day 14 post SIVmac251
intra-rectal challenge. Gating schematic is shown above, selecting for singlets, then
lymphocytes, then CD3+CD8+ T cells. Mamu-A*02/pl99RY tetramer positive cells were sorted
in parallel into FACS tubes filled with RNAprotect Reagent. A total of 33,000 pl99RY+ cells
were collected.
RNA was extracted from sorted virus epitope-specific CD8+ T cells using the Trizol method and
the RNA integrity was measured by an Agilent Bioanalyzer (Fig. 4.8).
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Figure 4.8. RNA integrity and quantity from tetramer positive cells on Day 14 post
SIVmac251 challenge for Mm107-2006 (A*01+) and Mm337-2008 (A*02+). The A01
restricted epitopes are pl 1C, TL8, and p54AS. The A*02 restricted epitope is p199RY. The
RNA was extracted using the Trizol method and integrity analysis was performed by Agilent
Bioanalyzer and all samples were resuspended in 5 ul RNase-free water.
For each sample that was collected at each timepoint, 500 pg of RNA was taken and
amplified using the TargetAmp 2-Round Biotin-aRNA Amplfication Kit 3.0 (Epicentre
Biotechnologies) to produce biotin-aRNA to be hybridized to the Illumina HumanHT-12
Expression Beadchip. A total of 1.5 ug of biotin-aRNA is required for hybridization. Table 4.1
and Figure 4.9 show a representative amplification from 500 pg of starting CD8+ T cell total
RNA.
Table 4.1 Amplified biotin-aRNA from total CD8+ T cells from Mm107-2006 (A*01+) and
Mm337-2008 (A*02+). Total RNA in the amount of 500 pg was amplified using the TargetAmp
2-Round Biotin-aRNA Amplification Kit 3.0 (Epicentre Biotechnologies) and resuspended in 40
ul RNase-free water. These samples were obtained 14 and 21 days before challenge to establish
baseline as well as to verify procedure. The No RNA Control was included as a negative control.
aRNA concentration (ng/ul) Total aRNA amt (ug)
107-2006 Total CD8 -21DPI 2543 101.72
337-2008 Total CD8 -21DPI 2467 98.68
107-2006 Total CD8 -14DPI 1804 72.16
337-2008 Total CD8 -14DPI 2079 83.16
No RNA control 30 1.2
70.30
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Figure 4.9. Amplified biotin-aRNA from total CD8+ T cells from Mm107-2006 (A*01+)
and Mm337-2008 (A*02+). Total RNA in the amount of 500 pg was amplified using the
TargetAmp 2-Round Biotin-aRNA Amplification Kit 3.0 (Epicentre Biotechnologies) and
resuspended in 40ul RNase-free water and measured on Nanodrop ND-1000. These samples
were obtained 14 and 21 days before challenge to establish the baseline as well as to verify the
procedure.
For some of the samples, enough total RNA was extracted from the cells to allow for one round
of amplification. For these samples, the remaining RNA that was not used for the two-round
amplification was amplified one-round with the Illumina(R) TotalPrep(TM) RNA Amplification
Kit (Ambion) and hybridized to the Illumina HumanHT-12 Expression Beadchip.
Tetramer responses
Weekly following SIVmac251 intra-rectal challenge, 10 ml of blood was obtained from 6
Mamu-A*01+ and 6 Mamu-A*02+ rhesus monkeys. PBMCs from Mamu-A*01+ rhesus
monkeys were stained with Mamu-A*01/pl 1C, Mamu-A*01/TL8, and Mamu-A*01/p54AS, and
PBMCs from Mamu-A*02+ rhesus monkeys were stained with Mamu-A*02/pl99RY tetramer.
Gating on CD3+CD8+ lymphocytes, tetramer-binding cells were detected by week 2 post-
infection (Fig. 4.10), consistent with previous reports.' 89 In some animals, the tetramer response
was already detectable by week one post-infection. Tat TL8-specific CD8+ T lymphocyte
responses peaked by 2 wk, and then rapidly declined. Gag pl 1C-specific CD8+ T lymphocyte
responses developed more slowly, were of lesser magnitude than the Tat TL8-specific responses,
and had more gradual increases and decreases. The Gag p11 C-specific CD8+ T lymphocyte
responses in monkeys 107-2006 and 112-2006 were bimodal. The subdominant Env p54AS-
specific CD8+ T lymphocyte response was much lesser than the dominant Gag pl1 C and Tat
TL8 responses and in monkey 125-2008, it was undetectable.
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Figure 4.10. Mamu-A*01-restricted, SIV epitope-specific T lymphocyte responses in
SIVmac251-infected Mamu-A*01+ rhesus monkeys. Shown are three of six monkeys intra-
rectally infected with SIVmac251. The development of T lymphocyte responses specific for the
Mamu-A* 01-restricted epitope Gag p1 1C, Tat TL8, and Env p54AS was monitored by tetramer
staining of PBMCs. Shown are the percentages of cells gated on the lymphocyte population that
stained positively for CD3, CD8a, and a soluble tetramer complex containing Mamu-A*01 and
the indicated epitope peptide. For monkeys 112-2006 and 125-2006, tetramer responses for later
timepoints are pending.
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Figure 4.11. Mamu-A*02-restricted, SIV epitope-specific T lymphocyte responses in
SIVmac251-infected Mamu-A*02+ rhesus monkeys. Shown are data from 3 or 6 monkeys
intra-rectally infected with SIVmac251. The development of T lymphocyte responses specific
for the Mamu-A*02-restricted epitope Nef p199RY was monitored by tetramer staining of
PBMCs. Shown are the percentages of cells gated on the lymphocyte population that stained
positively for CD3, CD8a, and a soluble tetramer complex containing Mamu-A*02 and p199RY.
For monkeys 116-2006 and 135-2006, tetramer responses for later timepoints are pending.
In the Mamu-A*02+ monkeys, Nef p199RY tetramer-binding CD8+ T lymphocytes were
detected by 2 wk post-infection and peaked by 2 or 3 wk post-infection (Fig. 4.11). The
magnitude of the tetramer response differed among animals with peak tetramer percentages of
CD8+ T lymphocytes ranging from 1.7% to 6%. This variability has also been seen in previous
studies. 189
Plasma Viral Loads
Plasma virus RNA levels were assessed over time in all experimental animals. Plasma viral
RNA levels are shown for 3 of the 6 pairs of A*01+ and A*02+ animals in Figure 4.12. The time
to peak viremia and magnitude of peak viremia was comparable between the groups of monkeys.
Virus RNA levels were consistent with tetramer CD8+ T lymphocyte responses (Fig. 4.10 and
4.11), showing the development of tetramer responses shortly after peak viremia.
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Figure 4.12. SIV viral load kinetics and magnitude for Mamu-A*01+ (A) and Mamu-
A*02+ (B) rhesus monkeys. Viral loads are given for 3 of the 6 pairs of A*01+ and A*02+
rhesus monkeys. For monkeys 112-2006, 125-2006, 116-2006, and 135-2006, viral loads for
later timepoints are pending.
Discussion
While results from this study are pending, there are two possible expected outcomes. One
possibility is that there is a difference between the Mamu-A*01 and Mamu-A*02 positive
monkeys that lies within the RNA transcripts of their respective virus epitope-specific CD8+ T
cells. Gene expression profiling will uncover any such differences and from there, the particular
gene targets can be validated by quantitative PCR, and various pathways can be explored with
the hope of elucidating underlying mechanisms of action. The other possible outcome is that
there is no difference in biology at the transcript level between the A*01 restricted CTLs and the
A*02 restricted CTLs. If that proves to be the case, we must look elsewhere for explanations for
the difference in viral control between the Mamu-A*01+ and Mamu-A*02+ monkeys.
There are factors that cannot be explored by gene expression profiling that may contribute to
differences in SIV control between Mamu-A*01 and Mamu-A*02 positive monkeys. For
example, recent studies in HIV-infected individuals have shown that the functional avidity of
HIV-specific CD8+ T cells are consistently higher and the tetramer dissociation rates
consistently lower in early infection as compared to chronic infection. 190 Further in vivo studies
have suggested that the functional avidity of CD8+ T cells is linked to their antiviral activity.
These data suggest that high-avidity HIV-specific CD8+ T cells recruited during early infection
might significantly contribute to the dramatic decline of HIV viremia during early infection.' 90
In converse, the loss of functional avidity by HIV-specific CD8+ T cells during chronic infection
may contribute to viral persistence and disease progression. 190 Extending these findings to our
current study, it is possible that there may be a difference in CTL TCR affinity for viral peptides
in association with MHC class I molecules in the Mamu-A*01+ and Mamu-A*02+ monkeys.
Another potential explanation for differences in SIV control between the Mamu-A*01+ and
Mamu-A*02+ monkeys is difference in mutation rates in the immunodominant epitopes. Due to
both the high replication rate of SIV and HIV and the high error rate of the RT encoded by HIV
and SIV, viral mutations are generated rapidly in a setting of significant immune selection
pressure conferred by the CTLs. Evidence of viral escape from CTL recognition has been shown
in both chronic and acute HIV infection, occurring as early as day 50 post-infection for the HLA-
B44-restricted epitope of gpl60 or the HLA-B8-restricted epitope of Nef.191'192 Mutations in
CTL epitopes have also been seen in both acute and chronic infection in SIV Nef, Env, Tat, and
Gag. 193 However, certain CTL epitopes are more restricted in their ability to tolerate amino acid
substitutions while other are more permissive for substitutions. 19 3 Studies by other groups have
shown a rapid emergence of Tat SL8 epitope variants 2 and slow emergence of Gag pl1 C epitope
variants. 3',194 -196 In a study of Mamu-A*01+ and Mamu-A*02+ animals infected with SIVmac251,
an increase in frequency of mutation in the immunodominant Nef p199RY epitopel 65 was shown,
where 78-100% of the virus in each monkey had mutations, and 26% of these mutations were in
the residues of the peptide that are most important for binding to Mamu-A*02.1
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,197' 198
Explanations for the variations in frequency of immunodominant epitope mutations include
differences in protein expression kinetics, CTL avidity, and structural constraints on the virus.' 93
The structural constraints explanation, however, is perhaps the most compelling. Viral escape
from CTL epitopes located within constrained regions of viral structural proteins may require
multiple compensatory mutations to facilitate assembly of viable virus. 193 The generation of
such compensatory mutations may occur infrequently during infection. 193 Unlike Tat, Nef, and
Env proteins, which can retain function with numerous mutations and even large deletions, the
structural Gag protein has limited tolerance for mutations. 199 Successful SIV/HIV escape from
CTL recognition likely requires a balance between the selection pressures exerted by CTL and
the maintenance of viral structural competency. The Gag p11C epitope is located in a highly
conserved region of the capsid protein, which has been shown by various groups to play a critical
role in SIV/HIV replication.200' 201 Mutations within the Gag pl1 C epitope are likely to interfere
with virus assembly, and therefore compensatory mutations are necessary to maintain a viable
virus. 193,202 The fitness costs of mutations in the Gag p1iC epitope limit viral escape from
CTLs. 20 3 The limited ability of SIV to escape from CTL at that dominant Gag epitope may
contribute to the superior control of SIV in the Mamu-A*01+ monkeys. The requirement for
coincident compensatory mutations may also explain why viral mutations in this epitope occur
more infrequently than they do in other epitopes. 193
CHAPTER 5: DISCUSSION
The work presented here paves the way for the study of rare cell populations in both peripheral
blood and mucosal tissues. The evolution of virus-specific CD8+ T lymphocytes in mucosal
compartments in the setting of primary SIV infection is not well understood. Most studies of
CD8+ T cells that have been carried out to date only evaluate peripheral blood or unfractionated
lymphocyte populations from mucosal specimens.24 4-206 While the present study is an analysis
of the evolution of virus-specific CD8+ T cells in the blood, one can build on this knowledge by
performing a similar study of virus-specific CD8+ T cells from mucosal compartments such as
the duodenum, distal colon, and from bronchoalveolar lavage specimens, using peripheral blood
virus-specific CD8+ T cells as a comparator. One can then ask the question if the biology or the
temporal evolution of virus-specific CD8+ T cells differ at the transcript level between the blood
and mucosa and between different mucosal compartments. The strategies presented in Chapters
2 and 3 can also be used to assess the evolution during primary infection of various other cell
populations, such as B cells, NK cells, and dendritic cells. While the majority of studies in the
HIV and SIV literature have focused on adaptive cellular immunity, the role of the innate
immune system has recently been implicated in HIV pathogenesis.207-21 3 A study of the evolution
of gene expression in innate immune cells in the setting of HIV or SIV infection should be very
useful to further our understanding of AIDS pathogenesis.
While immune responses to HIV or SIV depend on the expression of cellular genes,
understanding the entire picture of the immune response requires a more integrated approach.
While functional genomics strives to identify the role of genes in cellular processes by way of
hybridizing mRNA to complementary DNA, functional immunomics aim to identify roles of
chemical/biological targets involved in immunological processes by examining specific cellular
and humoral immune responses elicited by antigens presented to the immune system. 1' 10 2'214' 215
For example, antibody microarrays might be used to probe post-translational functional
genomics, since there has been some evidence of poor correlations between concentrations of
mRNAs and their corresponding proteins.216' 21 7 Other immunomic microarrays include those that
focus on peptide, cell, serum, and peptide-MHC. 218 Whereas DNA microarrays can only assay
one parameter (the level of transcription of each gene), immunomic microarrays can measure
several parameters pertaining to the immune responses against a single epitope. 218 For example,
in peptide-MHC arrays, not only can one assay binding to individual peptide-MHC complexes,
one can also assay the quantity and quality of the cytokine responses to these complexes. 218 The
complexity of statistical analyses for immunomic microarrays is significantly greater than for
DNA microarrays. While there are roughly 30,000 genes in humans, the number of different T
cell receptors generated by somatic recombination is estimated to be on the order of 107 to 1015.
In addition, DNA is composed of combinations of four different bases (A, T, C, G), while
peptide epitopes are composed of combinations of up to 20 different amino acids. While there
are many challenges, immunomics may eventually be an additional tool one can use to study T
cell immune responses to SIV or HIV.
Another technology that can be useful for studying immune responses in SIV and HIV infection
is the new generation of gene sequencing. Sequencing technologies such as 454 sequencing
technology, Illumina/Solexa, and ABI/SoLiD have had a tremendous impact on genomics
research. 2 19 These technologies can perform thousands of reactions in parallel and are more
cost-effective than traditional Sanger sequencing, and also replace troublesome in vivo cloning
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with in vitro clonal amplification using emulsion PCR or bridge amplification on solid
surfaces.219 The downside to these new sequencing methods is the shorter read lengths (35bp for
Solexa and ABI/SOLiD and 300bp for 454). 2 19  However, there are applications such as
sequence census that can benefit from short reads. The sequence census approach uses short
reads to establish the site of origin of the read instead of the whole sequence. 2  A novel use of
the sequence census approach identifies protein binding sites on the DNA using chromatin
immunoprecipitation followed by next-generation sequencing (ChIP-Seq). 2 19 This has been
applied to identification of transcription factor binding sites as well as histone modifications on a
genome-wide scale.219 The use of next generation sequencing technology for transcriptome
sequencing can provide insight into the level of gene expression, the structure of the genomic
loci, sequence variation present at loci, and profiling of noncoding RNA (e.g. tRNA, rRNA,
miRNA, and siRNA). 219-221
Lastly, single cell PCR, which was first described over a decade ago, has reached new levels of
accuracy and efficiency. Single cell PCR was first used in the area of fetal diagnostics,
researchers have increasingly used this technology for a number of different applications.222
Single cell PCR has been used in the analysis of TCR repertoires of CD8+ T cells in response to
antigenic challenge.22 3 Single-cell RT-PCR has enabled gene expression analysis of single cells.
This is powerful technology that can potentially allow for a complete analysis of very small
subpopulations of cells and even individual cells within a subpopulation. Single cells can be
obtained by laser mediated micromanipulation systems (e.g. laser capture microdissection) and
then assayed for mRNA expression.222 Combining single cell PCR with array analysis can
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provide a true analysis of the heterogeneity of the immune response in particular cell
subpopulations and can lead to new insights into cell-cell interactions and cellular dynamics.
There is much that is still unknown about the immune response following SIV and HIV infection.
However, new tools are currently being developed that in the coming years will provide new
ways of studying the immune response and lead to an increasingly better understanding of SIV
and HIV pathogenesis.
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